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Abstract 
Abstract 
T 
^ he occurrence of various forms of cancer has haunted mankind since 
prehistoric era. Modem lifestyle has only exaggerated the severity of the 
condition to mammoth levels. Despite continuous research on its early diagnosis, 
treatment to prevent or delay, this disease remains an unsolved puzzle. In a sui^e to 
discover new treatment modalities and therapeutics, various novel anti-cancer 
compounds and techniques have been developed. Though phytochemicals are 
considered to be wonder drugs of modem era having strong anti-cancer activities but are 
manifested with issues like solubility, stability and toxicity. Attainment of required 
concentration is another issue to be addressed. These associated problems retard tlieir 
translation into clinical settings. Nanotechnology provides a solution to these dilemmas 
and to date many nano and micro sized systems such as nanoparticles, liposomes and 
micelles have been developed. Among these technologies, nanoparticles and liposomes 
have gained much insight. Variety of polymers have been synthesized with different 
degradation periods to fulfil the need. These polymers are biodegradable, biocompatible 
and do not induce any immunogenic response inside the host. Ongoing research has 
implemented drug delivery systems against cancer treatment, a series of strategies have 
been developed and modified to enhance the therapeutic efficacy of these nanoparticle 
and liposome based formulations. A number of obstacles in in liw stability, bioavailability 
and non-tai^eted accumulation have impeded the clinical implication of these drug 
delivery systems. Those impediments have been partially resolved by scientific 
community significantly that resulted in various nanotechnology products in the market 
with enhanced efficacy. However, there are still certain demands to fulfil, particularly in 
the enhancement of tissue specificity and reduction in side effects. A principle barrier to 
destmction of disseminated cancer is its heterogeneous nature as most of the tumors 
Abstract 
contain cell subpopulations that subvert the host defences and initiate angiogenesis on 
their own and bear self sufficiency in growth factors. So those are the few barriers that 
limit application of available chemotherapeutic agents that we need to overcome. 
Most of the chemotherapeutic drugs fail to exhibit their desired effect as they do 
not reach at tai^eted site and are cleared from the systemic circulation before attainment 
of their required concentration. Therefore, high doses of the drugs need to be supplied 
that result in associated toxicity, another serious problem to tackle. There is consistent 
research on phytochemicals to provide an altemative to those available chemotherapeutic 
dmgs. Plant derived compounds inhibit multiple signaling pathways and induce 
apoptosis. Few compounds specifically recognize and kill cancer cells sparing adjacent 
healthy cells. But these compounds possess palatability and solubility issues. 
Nanotechnology provides a platform to meet the challenges concerned with application 
of these therapeutics. One can use either active targeting or passive mode of deliver\'. A 
plethora of nanoparticles have been used to target and deliver the therapeutics in the 
tissues. Perillyl alcohol, a monoterpene possesses strong anti-cancer activity but has not 
been utilised for its efficacy. 
In the first phase of the study, we encapsulated perillyl alcohol in poly lactic 
glycolic acid (PLGA) microparticles and characterized for their physical parameters like 
size, zeta-potential and release kinetics. Further, their toxicity was examined in utro by 
RBC lysis test and in ziio by measuring renal and hepatic enzyme functions. Those 
I 
formulations were evaluated for their inhibitory effect on epidermoid cancer cells (A253) 
in litro and on di ethyl benzo anthracene (DMBA) mduced skin papillomas. 
Qiaracterization data revealed that PLGA microparticles were bigger in size and showed 
sustained release of P O H As confirmed by RBC lysis test, semm creatinine and alkaline 
phosphatase (ALP) estimation, POH bearing PLGA formulation bears toxicity either in 
II 
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litro or in vm Micro and nanoparticles are known to be taken up by cancer cells more 
avidly, thus releasing high drug payload. To confirm our hypothesis, we evaluated 
inhibitory effect of our developed formulation on epidermoid cancer cell (A253). POH 
bearing PLGA microparticles bear more cytotoxic effect on epidermoid cancer cells than 
free form of POH. Western blotting results of apoptotic factors (p21/Wafl and Bax) 
revealed that POH bearing PLGA microparticles exerted more inhibitory effect in utm 
whereas free form of the drug failed to induce similar inhibition. Further, those 
formulations were examined for their in uzo activity by observing reduction in papilloma 
size, mortality rate, apoptosis induction and skin architecture. POH bearing PLGA 
microparticles being more stable exhibited highest reduction in papilloma size (80%) 
followed by free form of drug (60%). They had upregulated expression of p53 wild type 
and p21/Wafl, resulting downregulation of p53 mutant expression. Survival data also 
indicated that POH bearing PLGA micropamcles had maximum suni\al late (8C"/o) 
whereas free POH had only 40% survival rate. Skin tissue histology revealed that POH 
bearing PLGA microparticles regress skin papilloma much efficiently than free form ot 
the drug. Sham PLGA had no effect on mortality, tumor regression and apoptosis 
induction and they behaved as untreated control animals. Our data clearly established 
that POH bearing PLGA microparticles successfully inhibited epidermoid cancer cells in 
litrv and induced tumor regression thus increasmg the survival of treated animals. 
Curcumin (di fruloyl methane) found in lat^e quantities in the roots of Curcwm 
\lon§i, has been used as a spice and colouring agent in Indian and Chinese food Irom 
cenmries, also it has been utilised as a therapeutic agent. It possesses antioxidant, anti-
inflammatory properties and inhibits chemically induced carcinogenesis in the skin, fore-
stomach, colon, and liver. In spite of wonder molecule, its applications are limited 
because of hydrophobicity and poor absorption. In order to circumvent the 
III 
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hydrophobicity hurdle of curcumin in its in liw administration we developed a novel 
formulation. We encapsulated curcumin bearing PLGA microparticles in blank PC 
liposomes (microcells). Though PLGA microparticles also protect encapsulated 
molecules from external environment but they show burst release. We developed 
i 
microcells and PLGA microparticulate formulation of curcumin, characterized them and 
evaluated their efficacy in treatment of di ethyl nitrosamine (DEN) induced 
hepatocellular carcinoma in model animals. Besides being safe, these formulations do not 
bear any toxicity constraint as revealed by in utm and in uw studies. Upon encapsulation 
of PLGA particles in blank PC liposomes, they were found to release curcumin in a 
much sustained manner than curcumin bearing PLGA microparticles, also they did not 
show any burst release. Curcumin bearing microcells and PLGA microparticles based 
formulations were found to distribute curcumin to the tissues comparatively better than 
the free curcumin. The potential of those formulations to treat hepatocellular carcinoma 
was assessed by evaluation of liver enzymes alkaline phosphatase (ALP), aspartate 
transaminase (AST) and gamma glutamyl transferase (GGT). Owmg to their stabiliry and 
sustained release pattern, curcumin bearing PLGA microcells, were found to reduce the 
liver enzymes much efficiently than PLGA microparticles. PLGA microparticles were 
superior in liver enzyme reduction over free curcumin. TNF-a, a known factor that 
mediates timior cell differentiation and its survival was also examined in various 
curcumin formulations treated groups. Our results clearly established that microcells 
being more stable, released curcumin in a sustained manner and inhibited TNF-a 
I 
expression more efficiently than PLGA microparticles. Free form of curcumin had verv 
mild effect on TNF-ot expression. We also elucidated the pathway involved in regression 
of HCC by curcumin bearing microcells and PLGA microparticles formulations. 
Treatment with curcumin bearing microcells and PLGA microparticles was found to 
IV 
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modulate p53 wild type, bax and bcl-2 expression. Most significant upregulation in p53 
wild type and bax was observed in curcumin bearing microcells treated group 
formulations followed by PLGA microparticles. Also, those formulations were found to 
inhibit bcl-2 expression. Free form of curcumin did not modulate apoptotic factors 
much. Expression profile of p53 wild type, bax and bcl-2 established higher efficacy of 
curcumin bearing microcells and PLGA microparticles over free curcumin. Histological 
analysis also revealed that ciu-cumin bearing microcells helped in regression of HC(^ and 
maintenance of cellular architecture of liver. Curcumin bearing PLGA microparticles 
were also found to regress Uver cancer to some extent but not as significant as microcells. 
Sham microcells and PLGA microparticles had no effect neither on modulation of 
apoptotic factors nor on maintenance of tissues architecture. Ergo, we can conclude that 
encapsulation of curcumin in microcells and PLGA microparticles, increases its solubilit}' 
and bioavailability. These formulations were found to inhibit HCC growth efficiently in 
Swiss albino mice. 
In the last chapter of my thesis I have tried to overcome siElNA stability issue for 
its possible delivery inside cancer cells. With increasing knowledge of molecular 
mechanism of gene silencing using RNA interference, small interfering RNA (SLRNA) is 
now used for the treatment of incurable diseases like cancer. There are certain challenges 
to be accomplished before translation of siRNA therapy in clinical settings. Unspecific 
targeting, premature degradation and targeted delivery are few major challenges to 
resolve. Delivery of therapeutics at (required site plays an important role as most of 
treatment modalities require systemic administration. siE^NA delivery using 
nanotechnology based tools could be one such plausible solution for safe and target 
specific delivery of siRNA. COX-2 (Cyclo Oxygenase 2) is an important enzyme that 
helps in prostaglandin synthesis and has been reported to mediate carcinogenesis and 
V 
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angiogenesis in various cancer types. We developed minicells from Badllus subalis total 
lipid for the delivery of COX-2 siRNA and compared their efficacy with phosphatidyl 
choline (PQ liposomes. They were used to treat DEN induced hepatocarcinogenesis in 
model animals. Liposome mediated delivery of COX-2 siBNA helped in liver enzyme 
I 
reduction vz aspartate transaminase (AST) and alanine transaminase (ALT), and tumor 
regression in treated animals. Apoptosis measurement via APO-Brdu staining of liver 
cells also indicated that minicells bearing COX-2 inhibited DEN induced carcinogenesis 
much efficiently than PC liposomes. In addition, Western blotting of COX-2 and 
apoptotic molecules (p53 wild type and bax) revealed that minicells encapsulated COX-2 
siRNA downnegulated the expression of COX-2 significantly than PC liposomes and free 
siRNA. Upregulation of p53 wild type and bax and downregulation of bcl-2 expression 
was as a result of COX-2 inhibition. Histology of liver tissues and survival data also 
established that minicells mediated delivery of COX-2 siRNA helps in tumor regression, 
cellular morphology maintenance, and increases in survival of treated animals. Though 
free siRNA also imparts protection, increases survival and initiates apoptosis but not as 
significantly as minicells encapsulated siRNA and PC liposomes did. Minicells {B.sukiiis 
liposomes) being more stable exhibited comparatively higher regression and increased 
survival than PC liposomes. Our results demonstrated that minicells and PC liposomes 
mediated delivery of COX-2 siRNA saves it from premature degradation and 
successfully inhibits hepatocarcinogenesis in model animals. 
We can conclude that nanotechnology offers very promising tools that can be 
used for passive targeting. Various nanoparticle and liposome based approaches can be 
applied to overcome the solubility and bioavailability issues of drugs. Also those 
approaches can be availed for tissue specific delivery of siRNA molecules. 
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Chapter I: Review of literature 
(Part I: Cancer) 
Chapterl: Review of literature 
1.1 Cancer. A complex woiidwide scourge 
Cancer, or malignant neoplasm in medical definition, is the name given to a class of 
complex diseases in which groups of bodily cells display uncontrolled grouth that 
eventually leads to invasion of adjacent tissues, and sometimes metastasis, spreading to 
other locations in the body via lymph or blood. The spread of the malignant cells extends 
outward from the original tumor, and has been described as resembling the appearance 
of a crab. This is the origin of the term 'cancer", which was derived from the Latin 
meaning 'crab' (Walter 1977). Qncer is caused by genetic instability and accumulation of 
multiple molecular alterations (Hanahan & Weinbei^ 2000, Hahn & Weinberg 
2002). Any cell has the potential to undergo malignant changes and develop into cancer. 
This can occur when 'normal' cell control mechanisms become dismpted or indeed fail 
(Figure 1.1) (Comer 2001). The complexity of cancer is compounded by the cunent 
lack of effective diagnostic and prognostic tools that are cmcial for the prediction ot 
clinical heterogeneity of mmors and are insufficient for successful treatment and patient 
outcome (Liotta & Petricoin 2000, Petricoin 2002). 
Because of the lack of diagnosis, at the time of clinical presentation, more than 
60% of patients with cancer have hidden or overt metastatic colonies (Menon & Jacobs 
2000). At this stage, therapeutic modalities are limited in their effectiveness. Due to these 
problems, cancer has overtaken heart disease as the leading cause of death for adults in 
the United States (Figure 1.2) [United States Cancer Statistics, Centers for Disease 
Control and Prevention (CDC) http://www.cdc.gov/cancer/npcr/uscs]. The 
occurrence of cancer cases has been recorded since prehistoric era; modem life style has 
only exaggerated the condition. In 2008 approximately 12.7 million cancers 
were diagnosed and 7.6 million people died of cancer worldwide (Jemal et al. 
2011). Cancers as a group account for approximately 13% of all deaths each year with the 
most common being lung, stomach, colorectal, liver, and breast cancer (WHO 2006). 
This makes invasive cancer the leading catise of death in the developed world and the 
second leading cause of death in the developing world (Jemal et al. 2011). 
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Figuie 1.2 Cancer epidemiology worldwide. (Death rate from malignant cancer per 
100,000 inhabitants in 2004) (WHO 2009). 
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1.2 Classification 
I. Lymphoma is cancer of lymphatic cells of the immune system. Typically, 
lymphomas are present as a solid tumor of lymphoid cells. These malignant cells 
often originate in lymph nodes, presenting as an enlargement of the node (a 
tumor). It can also affect other organs in which case it is referred to as extra 
nodal lymphoma. Extra nodal sites include the skin, brain, bowels and bone. 
Lymphomas are closely related to lymphoid leukemia, which also originate in 
lymphocytes but typically involve only circulating blood and the bone marrow 
(where blood cells are generated in a process termed haematopoesis) and do noi 
usuaDy form static tumors. 
IL Cancer of blood or bone marrow, characterized by abnormal increase of white 
blood cells is called as Leukemia. Leukemia is a broad term covering a spectnim 
of diseases. In mm, it is part of the even broader group of diseases called 
hematological neoplasm. 
III. Germ cell tumor (GCT) is a neoplasm derived from germ cells. Germ cell 
tumors can be cancerous or non-cancerous. Germ cells normally occur inside the 
gonads (ovary and testis). Germ cell tumors that originate outside the gonads 
may be birth defects resulting from errors during development of the embn'o. 
IV. Blastoma is caused by malignancies in precursor cells, often called blasts. 
Examples are nephroblastoma, medulloblastoma and retinoblastoma. The suffix 
blastoma is used to imply a tumor of primitive, incompletely differentiated (or 
precursor) a ceU, ie, chondroblastoma is composed of cells resembling the 
precursor of chondrocytes. 
1.3 Causes of Cancer 
Cancer may be called an environmental disease as 90-95% of cases are due to 
environmental factors and merely 5-10% i due to genetics (Anand et al. 2008). 
"Environmental factors", include everything from natural sunlight to industrial pollution 
to viruses to behavioral choices to old age. Most environmental causes, such as naturallv 
occurring background radiation, are not modifiable or controllable. Common 
environmental factors that lead to cancer death include: tobacco (25-30% of deaths), diet 
and obesity (30-35%), infections (15-20%), radiation (both ionizing and non ionizing), 
stress and lack of physical activity (Anand et al. 2008). 
Chapterl: Review of literature 
I. Diet 
It is well recognized that a diet that is low in fiber and high in animal fats can significantly 
contribute to the development of colorectal cancer (Cartmel & Reid 2000, Yaibro & 
Fnogge et al 2005). It is estimated that a third of all cancers and possibly as man}^ as 
90% of colorectal malignancies are directly associated to diet (Yaibro et al. 2005). The 
development of cancer through dietary factors is not confined to colorectal malignancies. 
Diet which is high in fat content leads to the development of breast and stomach cancer 
also (Willett 1989, Sheppanl 2001). 
Tobacco: Decades of research has demonstrated the relation between tobacco use and 
cancer in the lung, larynx, head, neck, stomach, bladder, kidney, oesophagus and 
pancreas (Kuper et al. 2002). Tobacco smoke conuins over fifty knov,Ti carcinogens, 
including nitrosamines and polycyclic aromatic hydrocarbons (Kuper e? al. 2002). There 
is overwhelming evidence to link tobacco with a variety of cancers. Tobacco smoking is 
associated with many forms of cancer (Sasco et al. 2004), and causes 90% of lung 
cancer (Biesalski et al. 1998). The malignant conditions linked to the use of/exposure 
to tobacco includes (Horton-Taylor2001): 
Small cell (oat cell) carcinoma of the lung 
Orophamygeal cancer 
Bladder cancer 
Cervical cancer 
Gastric cancer 
Lip cancer 
Pancreatic cancer 
II. Infection 
Some cancers can be caused by infection. Upto 20% of total human cancers are caused 
by infections (Pagano et al. 2004). Viruses are the most common infectious agents that 
cause cancer. Bacterial infection may also increase the risk of cancer, as seen in 
Hdwoktcter p)ion induced gastric carcinoma (Pagano et al. 2004). Parasitic infections 
strongly associated with cancer are caused mainly by Sdnstosam haermtohium (squamous 
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cell carcinoma of the bladder) and the liver flukes, Cpisthonhis •dzerrim and Chnorxhis 
sinensis (cholangiocarcinoma) (Samaras etal. 2010). 
A. Viruses 
Viruses are one of the most important risk factor second to tobacco for cancer 
development in humans (zurHausen 1991). 
There are two types of cancers caused by viruses: 
a) Acutely transfonning viruses: the virus carries an overactive oncogene, and the 
infected cell becomes cancerous as soon as the overactive viral gene is expressed. 
b) Slowly Ixansformir^ viruses: the virus genome is inserted near a previously 
existing proto-oncogene in the genome of the infected cell. The virus causes 
overexpression of that proto-oncogene, which typicaUy induces uncontrolled cell 
division. Because the virus genes might not insert near enough to a proto-
oncogene to trigger the cancerous changes, and, even if optimally located, it 
might take some time to become activated; slowly transforming viruses usiulK-
cause tumors much longer after infection than the acutely transforming VIRISCJ . 
People wth chronic hepatitis B infection are more than 200 times more likely to develop 
liver cancer than uninfected people (Sung et al. 2000). Liver cancer is one of the most 
common causes of cancer-related deaths in the world, and is especially common in East 
Asia and parts of sub-Saharan Africa. 
Human papilloma vimses (HPV) are another particularly common cancer-causing 
virus. HPV is well-known for catising genital warts and essentially all cases of ceivical 
cancer, but it can also infect and cause cancer in several other parts of the body, 
including the larynx, lining of the mouth, nose, throat, anus, and esophagus. Herpes 
viruses are a third group of common cancer-causing viruses. Two types of herpes 
viruses have been associated with cancen the Epstein-Barr vims (EBV) and human 
herpes vims 8 (HHV-8) (Cohen & Jeffrey I 2000). EBV appears to cause all non 
keratinizing nasopharyngeal carcinomas and some cases of lymphoma, mcluding Burkitt's 
lymphoma (Cohen & Jeffrey I 2000). EBV has also been found in a variety of other 
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types of cancer cells, although its role in causing these other cancers is not weU 
established. HHV-8 causes all cases of Kaposi's sarcoma. 
HIV does not directly cause cancer, but it is associated with a number of malignancies, 
especially Kaposi's sarcoma, non-Hodgkin's lymphoma, anal cancer and cervical cancer. 
Kaposi's sarcoma is caused by human herpes virus 8. AIDS-related cases of anal cancer 
and cervical cancer are commonly caused by human papilloma virus. After HIV destroys 
the immune system, the body is no longer able to control these viruses, and the 
infections manifest as cancer ("Wood & Hanington 2005). 
B, Bacteria 
Hdiwkiaerpylori can live in the lining of the stomach and is linked to the development of 
gastric and duodenal ulcers. It is now known that there is a link between chronic ulcer 
disease and the development of malignancy. 
C. Parasites 
The parasites that cause schistosomiasis (bilharzia), especially S. haermtdniim, can cause 
bladder cancer and cancer at other sites (Mustacchi 2000). Inflammation tnggered by 
the wonm's eggs appears to be the mechanism by which squamous cell carcinoma of the 
bladder is caused (Mustacchi 2000). 
III. Radiation 
Sources of ionizing radiation, such as radon gas, can also lead to cancer. Radiation can 
cause cancer in most parts of the body, in all animals, and at any age, although radiation-
induced solid tumors usually take 10-15 years, and up to 40 years, to become clinically 
manifest, and radiation-induced leukemias typically require 2-10 years to appear (Little & 
John B 2000). Low-dose exposures, such as living near a nuclear power plant, are 
generally believed to have no or very little effect on cancer development (Litde & John 
B 2000). Radiation is a more potent source of cancer when it is combined with other 
cancer-causing agents, such as radon gas exposure plus smoking tobacco (Little & John 
B 2Q00). Major damage normally results in the cell dying, but smaller damage may leave a 
stable, partly functional cell that may be capable of proliferating and developing into 
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cancel, especially if tumot suppressor genes were damaged by die radiation (Litde & 
John B 2000). 
Prolonged exposure to ultraviolet radiation £tom the sun can lead to melanoma and other 
skin malignancies. Clear evidence establishes ultraviolet radiation, especially the medium 
wave UVB, as the cause of most non-melanoma skin cancers, which are the most 
common forms of cancer in the world (Cleaver ctaL 2000). 
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Figure L3 Proportion of cancer deaths attributed to non-genetic foctots. Estimated 
proportion of cancer in the United States in category of non-genetic cancer causes 
(Adapted from Doll and Pcto, 1981). 
Exposure to ionizing radiation can result in the following malignancies: 
• leukemia 
• thyroid cancer 
• squamous ceU carcinoma of the skin. 
IV. PoUution 
Increasing use of chlorofluorocarbons (CFCs) is leading to the destruction of the ozone 
layer, resulting in more ultraviolet radiation reaching the earth. This is a contributiiig 
factor to the increase in the number of skin cancers. Also vincompleted combustion of 
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coal and certain other materials generate di-methyl benzo anthracene and other 
carcinogens which causes skin and other type of ma%nancies. 
V. Chemicals 
In the United States, extensive epidemiological data had documented about the 
carcinogenic hazards of woriq)lace exposures, including asbestos, benzene, arsenic, 
nickel, polycyclic hydrocarbons and vinyl chloride (Colditz et al. 2006). 
Millions of workers run the risk of developing cancers such as lung cancer and 
mesothelioma from inhaling asbestos fibers and tobacco smoke, or leukemia from 
exposure to benzene at their workplaces ("WHO, 2007). The onset of the resuking 
malignancy, that is mesothelioma, could run over a period of many years from the initial 
exposure. The use of asbestos has now been greatly reduced. 
VI. Genetics 
With the development of molecular biology, new techniques are leading to the 
identification of genes which increase an mdividual's predisposition to develop cancer. 
Genes already identified include (Yarbro et al. 2005): 
RBI Retinoblastoma 
\XT1 Wilm's tumor 
APC Familial polyposis 
CDKN2 Dysplastic nevus syndrome 
FACC Fanconi's anemia 
BLM Bloom syndrome (associated with leukemia) 
BRCAl Breast and ovarian cancer 
BRCA2 Breast cancer 
Table 1.1: Chemicals/agents linked to specific cancers 
Chemical/Agent 
Mbeilc^ '"*'•' 
Pitch, soot, coal tar, oil 
Arsenic Sinuses 
Wool/leather/wood dust 
Cancer 
R/fesothelioma '^'-^ 
Squamous cell carcinoma of the skin, scrotum 
liver . . J W - - -"»•' '~ --' ' 
lung 
Nasal sinuses 
5^ 4.i:_B|adder '-^t- ;* 
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1.4 Molecular mechanism of cancer invasion 
Cancer cell lack regulation in its machinery that operates its division and proliferation. 
They divide and proliferate infinitely and bypass the apoptosis. Following are six basic 
alterations in a normal cell's physiology that lead to mmor development. 
1. Acquired capability: self sufficiency in growth signal 
A healthy cell requires growth signals to move from one stage to another. Those 
signals are translated via cell bound transmembrane receptors that bind with distinct 
class of signaling molecules: diffuse growth factors, extracellular matrix components, 
and cell to cell adhesion molecules. Cancer cells have the potential to mimic those 
growth signals and possess self sufficiency in proliferation. 
2. Insensitivity to growth signals 
Within a normal tissue, multiple anti-proliferative signals operate to maintain cellular 
quiescence and tissue homeostasis; these signals include both soluble growth 
inhibitors and immobilized inhibitors embedded in the extracellular matrix and on 
the surfaces of nearby cells. These growth-inhibitory signals, like their positively 
acting counterparts, are received by transmembrane cell surface receptors coupled to 
intracellular signaling circuits. Cancer cells bypass this mechanism by inhibiting those 
growth signals. 
3. Sustained angiogenesis 
Angiogenesis is the physiological process involving the growth of new blood 
vessels from pre-existing vessels. Tumors induce blood vessel growth (angiogenesis) 
by secreting various growth factors (VEGF). Growth factors such as bFGF and 
VEGF can induce capillary growth into the tumor. 
4. Evading apoptosis 
The ttimor-suppressor protein p53 accumulates when DNA is damaged due to a 
chain of biochemical factors. Part of this pathway includes a-interferon and [3 
interferon, which induce transcription of the p53 gene and result in the increase of 
10 
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p53 protein level and enhancement of cancer cell-apoptosis (Takaoka et al. 2003). 
p53 prevents the cell from replicating by stopping the cell cycle at Gl , or interphase, 
to give the cell time to repair, however it will induce apoptosis if damage is extensive 
and repair efforts fail. Any disruption in the regulation of the p53 or interferon gene, 
result in impaired apoptosis and the possible formation of tumors. 
5. Limidess replicative potential 
Three acquired capabilities: growth signal autonomy, insensitivity to antigrowth 
signals, and resistance to apoptosis-all lead to an uncoupling of a cell's growth 
program from signals in its environment. Most types of tumor cells that are 
propagated in culture appear to be immortalized, suggesting that limitless replicative 
potential is a phenotype that was acquired in iko during tumor progression and was 
essential for the development of their malignant growth state (Hayflick 1997). This 
result suggests that at some point during the course of multistep mmor progression, 
evolving premalignant cell populations exhaust their endowment of allowed 
doublings and can only complete their tumorigenic agenda by breaching the 
mortality barrier and acquiring unlimited replicative potential. 
6. Tissue invasion and metastasis 
Once tumor is formed, it starts invading the neighbor tissues and cancerous cell 
migrate through newly formed blood vessels and spreads in other organs of the 
body. This distant settlement of mmor cells is called as metastasis. 
1.5 Metastatic spread 
Suigical removal of the original tumor is not always a successful treatment in malignant 
disease, due to microscopic spread. Malignant tumors are often irregular in shape, with 
ill-defined margins (Wolfe 1986, "Walter 1977). The potential for microscopic spread 
occurs when the tissue surrotinding the visible ttimor appears to the eye (macroscopic 
examination) to be unaffected by cancer. Microscopic examination of the stii^ical 
resection margins can reveal the presence of malignant cells. If left untreated, these cells 
will result in localized recurrence of the cancer and eventual spread (metastasis). 
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As malignant cells replicate, they grow in an irregular pattern, infiltrating surrounding 
tissue which results in infiltration of the lymphatics and/or blood vessels. By gaining 
access to these vessels, malignant cells can be carried to other sites within the patient's 
body, where they replicate and grow (Figure 1.4) (Wolfe 1986, Walter 1977). In order 
to ensure that these malignant cells receive the nourishment they need to thrive, 
angiogenesis occurs. This is the formation of new blood vessels (Yarbro et al. 2005). 
I. Lymphatic Spread 
Malignant cells gain access to the lymphatic system and travel along the \'essels to 
the 'regional draining' lymph nodes (Walter 1977). The malignant cells establish 
themselves in regional nodes, where they replicate and eventually replace the 
lymph node with a ma%nant tumor that is, cancer. Malignant cells from this 
tumor can then travel, via the lymphatic system, to the next group of l^mph 
nodes, thereby spreading the malignancy throughout the body (Walter 1977). 
Lymphomas and squamous cell carcinoma of the head and neck are tvvo 
examples of where cancer commonly spreads via the lymphatic system (Yarbro 
etal.2005). 
II. Blood Spread 
Mal^an t cells can also infiltrate the vascular system and travel along the vessels 
until they arrive at an area where they can become lodged and subsequently 
replicate to form a secondary (metastatic) deposit. The malignant cells can then 
migrate via the smaller blood vessels that is, the capillaries (Walter 1977). 
However, there is evidence that only a small percentage of cells entering the 
vascular system actually survive to give rise to blood-bome metastatic spread 
(Walter 1977). Malignancies which are linked to blood-bome spread include 
melanoma and small cell carcinoma of the lung (Yarbro et al. 2005). 
12 
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Figure 1.4 Metastatic spread: Primary tumor formatioa leads to angiogenesis, which 
eventually results in detachment and drcularion of cancerous cells to other part of body. 
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1.6 Treatment strategies for cancer 
Deep knowledge of cancer invasion and its proliferation has given rise to various 
technologies for the treatment of cancer. The choice of therapy depends upon the 
location and grade of the tumor and stage of the disease. Complete removal of the cancer 
(without damage to the rest of the body is the goal of treatment. Sometimes this can be 
accomplished by surgery, but the propensity of cancers to invade adjacent tissue or to 
spread to distant sites by microscopic metastasis often limits its effectiveness. The 
effectiveness of chemotherapy is often limited by toxicity to other tissues in the body. 
Radiation can also cause damage to normal tissue. Following are the few treatment 
modalities used for the treatment. 
A. Radiation therapy 
Radiation therapy uses high ene r^ radiation to kill cancer cells by damaging their 
DNA (Lawrence et al. 2008). X-ra\'s, gamma ra}'s, and chained particles are 
types of radiation used for cancer treatment. The radiation used for cancer 
treatment may come from a machine outside the body, or it may come 
from radioactive material placed in the body near tumor cells or injected into the 
bloodstream. This is called as internal radiation therapy. Systemic radiation 
therapy uses radioactive substances, such as radioactive iodine, that travel in the 
blood to kill cancer cells. Some patients receive radiation therapy alone, and some 
receive radiation therapy in combination with chemotherapy. The main side 
effect of radiation therapy is that it not only kills cancerous cells but also heakhy 
cells that lie adjacent to them. Also if few cells are left irradiated, they tend to 
expand with time. So while performing radiation therapy it must be planned 
carefully and executed. 
B. Surgery 
Non-hematological cancers can be cured with the help of suigery, but this is only 
possible when tumor has not metastasized. Tumors grow locally, and then spread 
to the lymph nodes, then to the rest of the body. Even small localized tumors are 
increasingly recognized as possessing metastatic potential. 
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Ciyosurgeiy is a technique for freezing and killing abnormal cells. It is used to 
treat some kinds of cancer and some precancerous or noncancerous conditions, 
and can be used both inside the body and on the skin. Cryosurger}^ is an 
alternative to surgery for liver cancer that has not spread, for cancer that has 
spread to the liver from another site, for prostate cancer confined to the 
prostate gland, for a precancerous condition of the cervix, and for cancerous and 
noncancerous tumors of the bone. Cryosurgery may have fewer side effects than 
other types of treatments, and is less expensive and requires shorter recover,' 
times. The technique is still under study, and its long-term effectiveness is not 
known. 
C Targeted therapies 
Targeted therapy, which first became available in the late 1990s, has had a 
significant impact in the treatment of some types of cancer, and is current!}' a 
very active research area. This constitutes the use of agents specific for the 
deregulated proteins of cancer cells. Small molecule targeted therapv dmgs are 
generally inhibitos of enzymatic domains on mutated, over-expressed, or 
otherwise critical proteins wdthin the cancer cell. Prominent examples are the 
tyrosine kinase inhibitors imatinib (Gleevec/Glivec) and gefltinib (Iressa). 
Monoclonal antibody therapy is another strategy in which the therapeutic agent is 
an antibody which specifically binds to a protein on the surface the cancer cells. 
Examples include the anti-HER2/neu antibody trastxizumab (Herceptin) 
used in breast cancer, and the anti-CD20 antibody rituximab, used in a varietv 
of B-cell malignancies. Targeted therapy can also be done using small peptides 
(Zennami et al 2011), and aptamers (C^ris & Wagner 2011) that specifically 
target over expressed cell surface receptors or affected extracellular 
matrix surrounding the tumor. Radionuclides which are attached to these 
peptides (e.g. RGDs) eventually kill the cancer cell if the nuclide decays in the 
vicinity of the cell. Especially oligo- or multimers of these binding motifs are ol 
great interest, since this can lead to enhanced tumor specificity and avidity. 
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D. Immunotherapy 
Immunotherapy is a strategy that is des^ned to induce immune system of host to 
fight against the disease. Contemporary methods for generating an immune 
response against tumors include intravesical BCG immunotherapy (Didilescu 
2010), use of interferons (Hervas-Stubbs et al. 2011) and other cytokines 
(Nicholas & Lesinski 2011) to induce an immune response. Vaccines to 
generate specific immune responses are the subject of intensive research for a 
number of tumors, notably malignant melanoma and renal cell 
carcinoma. Sipuleucel-T is a vaccine-like strategy in late clinical trials for prostate 
cancer in which dendritic cells from the patient are loaded with prostatic acid 
phosphatase peptides to induce a specific immune response against prostate-
derived cells. 
E. Homional therapy 
The growth of some cancers can be inhibited by providing or blocking ceitain 
hormones. Common examples of hormone sensitive tumors include cenain t\pt'S 
of breast and prostate cancers. Removing or blocking estrogen or testosterone is 
often an important additional treatment. In certain cancers, administration ot 
hormone agonists, such as progestogens maybe therapeutically beneficial. 
F. Angiogenesis inhibitors 
Angiogenesis inhibitors prevent the extensive growth of blood vessels 
(angiogenesis) that tumors require to survive. Few drugs (Thapa et al. 2011) and 
monoclonal antibodies (Damasceno 2011) have been used to prevent 
angiogenesis in cancer tissues. Some, such as bevacizumab, have been approved 
and are in clinical use. But one of the main problems with ami-angiogenesis 
therapy is that many factors stimulate blood vessel growth in cells normal or 
cancerous. Anti-angiogenesis therapy only tai^ets one factor, so the other factors 
continue to stimulate blood vessel growth. Other problems include route of 
administration, maintenance of stability, activity and targeting at the tumor 
vasculature (Kleinman & Liau 2001). 
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G. Chemotherapy 
Qiemotheiapy is the treatment of cancer with anticancer drugs that can destroy 
cancer cells. Chemotherapeutic drugs interfere with cell division in vanous 
possible ways, e.g. with the duplication of DNAor the separation of newly 
formed chromosomes. Most forms of chemotherapy target all rapidly dividing 
cells and are not specific to cancer cells, although some degree of specificity may 
come from the inability of many cancer cells to repair DNA damage, while 
normal cells generally can. J^nce, chemotherapy has the potential to harm 
healthy tissue, especially those tissues that have a high replacement rate (e.g. 
intestinal lining). These cells usually repair themselves after chemotherap}-. 
Sometimes drugs are given in combination as they show better effect than alone, 
called as " combination chemotherapy". 
1.7 Phytochemicals in chemotherapy 
Cancer chemotherapeutic agents can often provide temporary relief from symptoms, 
prolongation of life and occasionally, cures. A successful anticancer drug should kill or 
incapacitate cancer cells without causing excessive damage to normal cells. This ideal 
situation is achievable by inducing apoptosis in cancer cells. The life span of both noirnal 
and cancer cells is significantly affected by the rate of apoptosis. Thus, modulating 
apoptosis may be useful in the management and therapy of cancer. Synthesis or 
modification of known drugs continues as an important aspect of research. However, a 
vast amount of synthetic work has contributed relatively small improvements over the 
prototype drugs. There is a continued need for new prototypes to use in the design of 
potential chemotherapeutic agents. Significantly, natural products are providing such 
templates. 
Recent studies on tumor inhibitory compounds of plant origin have yielded an 
impressive array of novel structures. Besides, epidemiological studies suggest that 
consumption of diets containing fruits and vegetables, major sources of phytochemicals 
and micronutrients, may reduce the risk of developing cancer. Certain products from 
plants are known to induce apoptosis in neoplastic cells but not in normal cells (Hirano 
et al 1995, Jiang et al. 1996). Those phytochemicals modulate different processes and 
shows cumulative inhibitory effect. Also they bear less or no toxicity constraint. 
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I. Alkylating agents 
All^ t ing agents function by forming covalent bonds with the amino, carboxyl, 
sulfhydryl, and phosphate groups in biologically important molecules. 
Qsplatin and carboplatin as weU as oxaliplatin are alkylating agents. Other agents 
include mecttoretharnine, cyclophosphamide, clorambusil and infosfamide. 
II. Anti-metabolites 
Anti-metabolites masqueradeas purines (azathioprine, mercaptopurine) 
or pyrimidines, which become the building blocks of DNA. They prevent these 
substances from becoming incorporated in to DNA during the "S" phase (ot 
the cell cycle), stopping normal development and division. They also affect RNA 
synthesis. Due to their efficiency, these drugs are the most uadely used 
cytostatics. 
III. Plant alkaloids 
Alkaloids are derived from plants and block cell division b\' pre\'entiiig 
microtubule function. Micrombules are vital for cell division and its inhibition 
blocks the process. Examples are vinca alkaloids and taxanes. They are derived 
from the Madagascar periwinkle, Catharamhus roseus (formerly known as Vinca 
Tcsea). The vinca alkaloids include: Vincristine, Vinblastine, Vinorelbine and 
Vindesine. 
IV. Terpenoids 
Terpenoids are another category of phytochemicals that possess strong anti-
cancer activity. Monoterpenes such as D-limonene and perillyl alcohol (POH) 
derived from orange peels and lavender, respectively possess chemopreventive 
properties against mammary, liver and lung carcinogenesis. 
V. Podophyllotoxin 
Podoph)ilotoxin is a plant derived compound'which is said to help with digestion 
as well as used to produce two other cytostatic dmgs, etoposide and teniposide. 
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They prevent the cell from entering the Gl phase (the start of DNA replication) 
and the replication of DNA (the S phase). The exact mechanism of its action is 
not yet known. 
VI. Taxanes 
The prototype taxane is the natural product paclitaxel, originally known 
i 
as Taxol and first derived from the bark of the Pacific Yew tree. Docetaxel is a 
semi-synthetic analogue of paclitaxel. Taxanes enhance stability of microtubules, 
preventing the separation of chromosomes during anaphase. 
VII. Topoisomerase inhibitors 
Topoisomerases are essential enzymes that maintain the topology of DNA. 
Inhibition of type I or type II topoisomerases interferes uith 
both transcription and replication of DNA by upsetting proper DNA 
supercoiling. 
A. Type I topoisomerase inhibitors include campothecins: iiinotecan 
and topotecan. 
B. Type II inhibitors include amsacrine, etoposide, etoposicie 
phosphate and tempos ide 
VIII. Polyphenols 
The human diet contains a complex mixture of plant polyphenols. Studies ha\ e 
shown that cytotoxic effect of these phenols against different tumors is mediated 
through apoptosis (Inoue et al. 1994). Gallic acid, curcumin and caffeic acid are 
known polyphenols that inhibit cancer cells proliferation (Reuter et al. 2011). 
IX. Flavonoids 
Flavonoids varied significantly in their antiproliferative potency depending on the 
structural features. Kuntz et al. found that flavonoids baicalein and myricetin 
were able to induce apoptosis in ITr-29 and Caco-2 cells. Flavonoids of the 
flavone, flavonol, flavanone and isoflavone classes possess antiproliferative 
effects in different cancer cell lines (Kuntz et al. 1999). 
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2.1 Nanotechnology in the treatment of cancer 
The past quarter century of outstanding progress in fundamental cancer biology has not 
translated into even distandy comparable advances in the clinic. Irmdequades in the 
ability to administer therapeutic moieties so that they will selectively reach the desired 
targets with mai^;inal or no collateral damage has largely accounted for the discrepancy 
(Langet 1998, Duncan 2003). Most striking is the recognition that only between 1 and 
10 parts per 100,000 of intravenously administered monoclonal antibodies reach their 
parenchymal ta ints in vim (Li et aL 2004). 
Nanotechnology concerns the 
study of devices that arc 
themselves or have essential 
components in the 1-1,000 nm 
dimensional range (that is, 
bova. a few atoms to subcellular 
size)." (Ferrari M. 2005) 
Similar limitations apply to contrast agents for imaging applications. There are two goals 
that should be kept in mind to increase the efficacy per dose of any therapeutic or 
imaging contrast formvilarion: firstly, to increase its targeting selectivity (Allen 2002) and 
second to endow the agent(s) comprising the therapeutic formulation with the means to 
overcome the biological barriers that prevent it from reaching its target Qain 1998). An 
ideal therapeutic system would be selectively directed against cell clusters Aat are in the 
early stages of the transformation towards the malignant phenotype. To make diose goals 
achievable there are certain hurdles, those include: identification of suitable early markers 
of cancerous cells, and to understand their evolution over time. Tackling those issues 
could help nanotechnologist to overcome above stated issues for the site directed 
delivery of therapeutic and imaging agents. 
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Current problems and unmet needs in translational oncology include (a) advanced 
technologies for tumor imaging and early detection, (b) new methods for accurate 
diagnosis and prognosis, (c) strategies to overcome the toxicity and adverse side effects 
of chemotherapy drugs, and (d) basic discovery in cancer biology leading to new 
knowledge for treating ^gressive and lethal cancer phenotypes such as bone metastasis. 
i 
Understanding those basic parameters of cancer biology will help scientist to develop 
therapeutic and diagnosis modalities for the early detection and effective treatment of 
cancer. 
"What is cancer nanotechnology? 
Cancer nanotechnology is new emerging multidisciplinary field that combines chemistry', 
engineering, physics, biology and medicine disciplines, and is expected to bring about 
revolution in cancer prognosis, diagnosis and treatment. 
Nanoparticles are nano sized materials (diameter 1-1000 nm) that can carry nuikiple 
drugs and/or imaging agents. Owing to their high surface-area-to-volume ratio, ii is 
possible to achieve high ligand density on the surface for tai^eting puiposes. 
Nanoparticles can also be used to increase local drug concentration by carrying the drag 
within and control releasing it when bound to the tai^ets. Currently, natural and synthetic 
polymers and lipids are typically used as drug delivery vectors. The family of 
nanoparticles includes polymer conjugates, polymeric nanoparticles, lipid-based carriers 
such as liposomes and micelles, dendrimers, carbon nanotubes, and gold nanoparticles, 
including nanoshells and nanocages (Figure 1.5). These nanocarriers have been explored 
for a variety of applications such as drug delivery, imaging, photo-thermal ablation of 
tumors, radiation sensitizers, detection of apoptosis, and sentinel lymph node mapping 
(Duncan 2005, La Van 2003). 
Nanocarriers can offer many advantages over free drugs. They: 
• protect the drug from premature degradation; 
• prevent drugs from prematurely interacting with the biological environment; 
• enhance absorption of the drugs in a selected tissue (for example, solid tumor); 
• control the pharmacokinetic and drug tissue distribution profile; 
• improve intracellular penetration. 
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For rapid and effective clinical translation, the nanocarrier should: 
• be made from a material that is biodegradable and biocompatible. 
• well characterized, and easily functionalized. 
• exhibit high differential uptake efficiency in the target cells over normal cells. 
i 
• be either soluble or colloidal under aqueous conditions; 
• have an extended circulating half-life, a low rate of aggregation, and a long shelf 
life. 
A. Nanowires 
Nanowires are available in metallic, semiconductor, magnetic, oxide, and polymer 
compositions and are promising as ultra small chemical and biological sensors (Wang et 
al. 2005). Ftmctionalized nanowires are coated with capture Hgands such as antibodies or 
oligonucleotides. In the presence of tai^et molecules, the specific binding between target 
molecule and capture molecule generates an immediate conductivit}' change within ihe 
nanowire that can be measured. Zheng et al. has developed nanowire an-a\^ tor 
multiplexed cancer biomarker detection (Zheng et al. 2005). Each nanov^ire ot 
mukiplexed system is coated with a distinct surface receptor capable of binding and 
sensing cancer biomarkers such as PSA, PSA-al-antichymotrypsin, carcinoembiyonic 
antigen, and mucin-1 in undiluted serum samples. These nanowire arrays allow 
simuluneous incorporation of control nanowires, which enables discrimination against 
false positives. 
B. Cantilevers 
Nanocantilevers-based sensors fvmctions on the principal that biomolecular binding 
events results in a change in their resonating frequencies (Fritz et al. 2000). The 
nanoscale dimensions offer the possibility of designing structures with mukiple such 
components, each with distinct detection capabilities, which can allow the simukaneous 
profiling of a range of markers for a given cancer. Furthermore, the reduction in the 
dimension also holds the promise of increasing the senskivity to a scale where k is 
possible to detect subtle changes in the profile. Molecular probes, such as smgle-stranded 
DNA, can also be attached to beams just a few nanometers thick. When exposed to a 
DNA sample, complementary strands bind to the probes on the cantilever, causing the 
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beams to bend slightly. That response can be detected visually or by a change in the 
beams'electrical conductivity. 
C Nanobarcodes 
An innovative approach for both proteip and nucleic acid detection based on bio 
barcode-amplification (BCA) has been developed (Nam et al. 2004). This approach uses 
both colloidal gold nanoparticles and magnetic microbeads, in which gold nanoparticles 
are modified with both target capture strands and bar code strands that are subsequently 
hybridized to bar code DNA, and magnetic microparticles modified with target capture 
strands. In the presence of target DNA, the gold nanoparticles and the magnetic 
microbeads form sandwich stmctvires that are magnetically separated from solution and 
are ftirther washed to remove the unhybridized bar code DNA. The bar codes (hundreds 
to thousands per target) are detected by using a colorimetric method. This integrated 
capture and detection technology is four to six orders of magnitude more sensitive than 
standard ELISA (enzyme-linked immune sorbent assay) for proteins and offers 
comparable sensitivities as P Q l (polymerase chain reactions) (Nam et al. 2004). 
D. Quantum dots (QDs) 
Semiconductor quantum dots (QDs) are tiny light-emitting particles on the nanometer 
scale that are emerging as a new class of fluorescent probes for in vivo biomolecular and 
cellular imaging (Alivisatos 2004, Alivisatos 1996, Alivisatos et al. 2005, Pinaud et al. 
2006, Michalet et al. 2005, Gao et al. 2005, Smith et al. 2004, Chan et al. 20C2) 
(Figure 1.5). They are made of inorganic elements such as cadmium or mercury encased 
in latex or metal and respond to light by emitting fluorescence at different vi^velengths 
and intensities depending on their composition. Antibodies attached to the crystals can 
cause the dots to bind to a selective tissue, such as a tumor, which can then be more 
easily seen with conventional imaging devices. Also in comparison with organic dyes and 
fluorescent proteins, QDs have unique optical and electronic properties. QDs have 
molar extinction coefficients that are 10-50 times larger than that of organic dyes, which 
makes them much brighter in photon-limited in uw conditions. Further, Q D emission 
wavelengths are size-tunable. For example, CdSe/Zns QDs of approximately 2 nm in 
diameter produce a blue emission, whereas QDs approximately 7 nm in diameter emit 
red light (Yu et al. 2003). Recently scientists have extended the emission wavelength 
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into the near infiated (650 om to 950 nm), to take advantage of the improved tissue 
penetration depth and reduced background fluorescence at these wavelengtlis ( f i m et 
al 2005). 
E. Carbon Nanotubes 
Another type of nanodevice for biotnarker detection is carbon nanotubes (CNTs) 
(Wong et oL 1998). Using single-walled carbon nanotubes as high-resolution atomic 
force microscopy (AFM) tips, specific sequences of kilobase-size DNA can be selectiv^ely 
detected from single-base mismatch sequences (Woolley et al 2000). SpecificaUy, target 
DNA fragments were first hybridized with labeled (for instance, strepavidin-labeled) 
oligonucleotides, and then AFM was used to directly detect the presence and specific 
location of the labels. This technique enabled the simple and direct detection of specific 
haplotypes that code for genetic disorders such as cancer. CNT-modified electrodes can 
amplify the electrochemical signal of guanuine bases. Those bases are used for label-free 
electrochemical detection of DNA at nanomolar concentrations (Wang et al 2004). 
Figure 1.5 Semiconductor quantum dots with quantum confinement and size-
tunable optical properties. This image shows ten distinguishable emission colors of 
ZnS-capped CdSe quantum dots excited with a near-UV lamp. From left to right (blue to 
red), the emission maxima are located at 443, 473, 481, 500, 518, 543, 565, 587, 610, and 
655 nm (adapted from Nie S etal. 2007). 
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F. Lipid-based nanocaniers 
They have attractive biological properties, including general biocompatibUity, 
biodegradability, isolation of drugs from the surrounding environment, and the ability to 
entrap both hydrophilic and hydrophobic drugs. Through the addition of agents to the 
lipid membrane or by the alteration of the surface chemistry, properties of lipid-based 
carriers, such as their size, chaise, and surface functionality, can easily be modified. 
Liposomes, polymersomes, and micelles represent a class of amphiphile-based particles. 
a) Liposomes are spherical, self-closed stmctures formed by one or several 
concentric lipid bilaysrs with inner aqueous phases. Today, Liposomes are 
approved by regulatory agencies to carry a range of chemotherapeutics (Gabizon 
2001(a), Gabizon 2001(b). Safia et al 2000). 
b) Polymersomes have architecture similar to that of liposomes, but they are 
composed of synthetic polymer amphiphiles, including PLA-based copolymers 
(Ahmed et al. 2006, Discher et al. 2006). However, as uith poKmer 
therapeutics, there are still no clinically approved strategies that use active cellular 
targeting for lipid-based carriers. 
c) Micelles are self-assembling closed lipid monolayers with a hydrophobic core 
and hydrophilic shell, have been successfully used as pharmaceutical carriers for 
water-insoluble drugs (Matsumura et al. 2004). They belong to a group of 
amphiphilic colloids that can be formed spontaneously under certain 
concentrations and temperatures from amphiphilic or surface-active agents 
(surfactants) (Figure 6a). An example of a polymeric micelle under clinical 
evaluation is NK911, which is a block copolymer of PEG and poly aspartic acid. 
NK911, which consists of a bound doxombicin fraction (-45%) (Figure 6b) 
and a free drug (Kato et al. 2006), was evaluated for metastatic pancreatic cancer 
treatment. Another carrier NK105, a micelle containing pacHtaxel, was evaluated 
for pancreatic, colonic and gastric tumor treatment (Torchilin 2007). 
Lipid-based carriers pose several challenges, which represent general issues in the use of 
other targeted nanocaniers such as polymeric nanoparticles. For example, upon 
intravenotis injection, particles are rapidly cleared from the bloodstream ' by the 
reticuloendothelial defense mechanism, regardless of particle composition (Brigger et 
al. 2002, Kreuter & Higuchi 1979). Moreover, instability of the carrier and burst dmg 
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release, as well as non-specific uptake by the mononuclear phagocytic system (MPS), 
provides additional challenges for translating these carriers to the clinic. Given their long 
history, liposome-based carriers serve as a classic example of the challenges encountered 
in the development of nanocarriers and the solutions that have been attempted. For 
example, PEG has been used to improve circulation time by stabilizing and protecting 
micelles and liposomes from opsonization - a plasma protein deposition process that 
signals Kupffer cells in the liver to remove the carriers from circulation (Matsumura et 
al. 2004, Damascelli et al. 2001). However, Daunosome and Myocet are examples of 
clinically used liposomes (80-90 nm in diameter) without PEG coating that have been 
reported to exhibit enhanced circulation times, although to a lesser degree than 
PEGylated liposomes such as Doxil/Caelyx. 
G. Dendrimers 
They are synthetic, branched macromolecules that form a tree-like structure and is a 
newly developed technology in the field of polymer chemistry. Polyamidoamine 
dendrimers have sho"^Ti promise for biomedical applications because they (1) can he 
easily conjugated with targeting molecules, imaging agents, and drugs, (2) have high water 
solubility and well-defined chemical structures, (3) are biocompatible, and (4) are rapidly 
cleared from the blood through the kidneys, made possible by their small size (<5 nni), 
which eliminates the need for biodegradability. /n izio delivery of dendrimer-methotrexate 
conjugates using multivalent targeting results in a tenfold reduction in tumor size 
compared with that achieved with the same molar concentration of free systemic 
methotrexate (Hong et al. 2007). Although promising, dendrimers are more expensi\'e 
than other nanoparticles and require many repetitive steps for synthesis, posing a 
challenge for lar^e-scale production. 
H. Nanoshells 
Dual-modality and multifunctional probes are being developed by attaching molecular 
moieties with imaging, therapeutic, and targeting functions to nanostructured scaffolds. 
These integrated nanoparticle probes may allow simultaneous imaging and therapy of 
tumors and cardiovascular plaques in live animal models. Solid silica nanospheres, 
sometimes encased in a thin layer of gold, will travel through the bloodstream without 
entering most healthy tissues, but they tend to accumulate in tumor tissue. Therapeutic 
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molecules can be attached to the spheres, or once a large number of the nanoshells 
accumulate in a tumor. Depending on their composition, nanoshells can also absorb or 
scatter light, enhancing tumor images made with certain forms of spectroscopy. 
Nanoshells (100-200 nm) may use the same carrier for both imaging and therapy. They 
are composed of a silica core and a metallic outer la)/er. Nanoshells have optical 
resonances that can be adjusted to absorb or scatter essentially anywhere in the 
electromagnetic spectrum, including the near infrared region (MR, 820 nm, 4 W cm'^, 
where transmission of light through tissue is optimal. Absorbing nanoshells are suitable 
for hyperthermia-based therapeutics, where the nanoshells absorb radiation and heat up 
the surrounding cancer tissue. Scattering nanoshells, on the other hand, are desirable as 
contrast agents for imaging applications. Recently, a cancer therapy was developed based 
on absorption of NIR light by nanoshells, resulting in rapid localized heating to 
selectively Idll tumors implanted in mice. Tissues heated above the thermal damage 
threshold displayed coagulation, cell shrinkage and loss of nuclear staining, which are 
indicators of irreversible thermal damage, whereas control tissues appeared undamaged 
(Hirsch et al. 2003, Loo et al. 2005). 
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Figure L6 Nanocamets for taigetiiig cancer. A. A whole range of delivery agents are 
possible but the main components typically include a nanocartier, a targeting moiety 
conjugated to the nanocartier, and a cargo (such as the desired chemotherapeutic drugs). 
B. Schematic diagram of the drug conjugation and entrapment processes. The 
chemotherapeutics could be bound to the nanocartier, as in the use of polymer drug 
conjugates, dendrimers and some particulate carriers, or they could be entrapped inside 
the nanocartier (adapted from Peer et al. 2007). 
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I. Nanocages 
A similar approach involves gold nanocages which are smaller (<50 nm) than the 
nanoshells. These gold nanocages can be constructed to generate heat in response to 
M R light and thus may also be useful in hyperthermia-based therapeutics (Chen et al. 
2005). Unlike nanoshells and nanocages, pure gold nanoparticles are relatively easy to 
synthesize and manipulate. Non-specific interactions that cause toxicity in healthy tissues 
may impede the use of many types of nanoparticles, but using inorganic particles for 
photo-ablation significandy limits non-specific toxicity because light is locally directed. 
However, inorganic particles may not provide advantages over other types of 
nanoparticles for systemic targeting of individual cancer cells because they are not 
biodegradable or small enough to be cleared easily, resulting in potential accumulation in 
the body, which may cause long-term toxicity. 
J. Nanoparticles 
Particles composed of a variety of materials can be constructed to contain therapeutic 
molecules in their core and to release them at a desirable time and location. Such deliver}-
vehicles include simple lipid sheUs that passively leak through tumor blood vessel walls, 
and then slowly release a traditional chemotherapy dmg into the tissue. Newer 
nanoparticles are more complexly designed, including exterior elements such as 
antibodies to target ttimor-specific proteins, and materials that minimize the particles 
interaction with healthy tissues. 
Inorganic nanoparticles are primarily metal based and have the potential to be produced 
with near monodispersity. Inorganic particles may also be functionalized to introduce 
targeting molecules and drugs. Specific types of recently developed inorganic 
nanoparticles include nanoshells and gold nanoparticles. 
2.2 implication of nanotechnology in cancer therapy 
Most current anticancer agents do not greatly differentiate between cancerous and 
normal cells, leading to systemic toxicity and adverse effects. Consequently, systemic 
applications of these drugs often cause severe side effects in other tissues (such as bone 
marrow suppression, cardiomyopathy, and neurotoxicity), which greatly limits the 
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maximal allowable dose of the drug. In addition, rapid elimination and widespread 
distribution into non-tai^eted organs and tissues requires the administration of a drug in 
large quantities, which is not economical and often complicated owing to non-specific 
toxicity. Nanotechnology offers a more targeted approach and could thus provide 
significant benefits to cancer patients. In fact, the use of nanoparticles for drug delivery' 
and targeting is likely one of the most exciting and clinically important applications of 
cancer nanotechnology. 
1. Passive Targeting 
Rapid vasculari2ation in fast-growing cancerous tissues is known to resuk in leaky, 
defective architecture and impaired lymphatic drainage. This structure allows an EPR 
(Enhanced Permeability and Retention) effect (Matsumura & Maeda 1986, Duncan 
2003, Jain 2001, Jain 1999), resulting in the accumulation of nanoparticles at the tumor 
site (Figure 1.7). For such a passive targeting mechanism to work, the size and surface 
properties of drug delivery nanoparticles must be controlled to avoid uptake bv the 
reticuloendothelial system (RES) (Gref et al. 1994). To maximize circulation times and 
targeting ability, the size should be optimized and the surface should be hydrophilic to 
circumvent clearance by macrophages. The hydrophilic surface of the nanoparticles 
safeguards against plasma protein adsorption and can be achieved through hydrophilic 
polymer coatings such as PEG, poloxamines, poloxamers, polysaccharides, or through 
the use of branched or block amphiphiHc copolymers (Rings dorf 1975, Davis 2002, 
Moghimi & Hunter 2000, Park et al. 2005). The covalent linkage of amphiphilic 
copolymers (polylactic acid, polycaprolactone, polycyanonacrylate chemically coupled to 
PEG) is generally preferred, as it avoids aggregation and ligand desorption when in 
contact with blood components. 
An akemative passive targeting strategy is to utilize the unique tumor environment in a 
scheme called tumor-activated prodmg therapy. The dmg is conjugated to tumor-specific 
molecule and remains inactive until k reaches the target (Chari 1998). Overexpression of 
the matrix metalloproteinase (MMP) MMP-2 in melanoma has been shown in a number 
of preclinical as well as clinical investigations (Mansour et al. 2003). Water-soluble 
maleimide derivative of doxorubicin (DOXj incorporating an MMP-2-specific peptide 
sequence (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gb), rapidly and selectively binds to the 
cysteine-34 position of circulating albumin. The albumin-DOX conjugate is efficiently 
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and specifically cleaved by MMP-2, releasing a DOX teteapepride (Ile-Ala-Gly-Gln-
DOX) and subsequendy DOX. pH and redox potential have been also explored as diug 
release t t i^ers at the tumor site (Guo & Szoka 2003). Another passive t a s t i n g 
method is the direct local delivery of anticancer agents to tumors. This approach has the 
obvious advantage of excluding the drug from the systemic circulation. However, 
administration can be highly invasive, as it involves injections or suurgical procedures. 
Normat tissue region: 
Exposure to nanopartides is 
minimal since the nanopartides 
are retained In the bloodstream 
Nanopartide 
Tumor tissue region: 
Leaky vasculature allows 
nanopartide accumulation 
in the interstitial space 
Figiure 1.7 Enhanced penneability and retention of nanopartides in tumors. 
Normal tissue vasculatures are lined by tight endothelial cells, thereby preventing 
nanopartide drugs from escaping or extravasation, whereas tumor tissue vasculatures are 
leaking and hypcrpetmeable allowing preferential accvimulation of nanopartides in the 
tumor interstitial space (called passive nanopartide tumor targeting) (adapted £rom Nie 
era/. 2007). 
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2. Active Targeting 
Active targeting is usually achieved by conjugating nanopaiticle with a targeting component 
that provides preferential accumulation of nanopaiticles in the tumor bearing oigan, in the 
tumor itself, individual cancer cells, or intracellular organelles inside cancer cells. This 
approach is based on specific interactions, such as lectin carbohydrate, ligand-receptor, and 
antibody-antigen (Allen 2002). Lectin-carbohydrate is one of the classic examples of 
targeted drug delivery (Kannagi et al. 2004). Lectins are proteins of non-immunological 
or^in, capable of recognizing and binding to glycoproteins expressed on cell surfaces. 
Lectin interactions wth certain carbohydrates are very specific. Qrbohydrate moieties can 
be used to target drug delivery systems to lectins (direct lectin targeting), and lectins can be 
used as targeting moieties to target cell surface carbohydrates (reverse lectin targeting). 
However, drug delivery systems based on lectin-carbohydrate have mainly been developed 
to target whole organs (Yamazaki et al. 2000), which can pose harm to normal cells. 
Therefore, in most cases the targeting moiety is directed towards specific receptors or 
antigens expressed on the plasma membrane or elsewhere at the tumor site. Ihe 
overexpression of receptors or antigens in many human cancers lends itself to efficieni drug 
uptake via receptor-mediated endoc}tosis (Figure 1.8). Because glycoproteins canrioi 
remove polvTner-dmg conjugates that have entered the cells via endocHOSis (Bennis et al. 
1994, Larsen et al. 2000), this active targeting mechanism provides an alternative route ior 
overcoming multiple drug resistance (MDR) (Links & Brown 1999, Krishna & Mayer 
2000, Vauthier et al. 2003, deVerdiere 1997, Blagosklonny 2003, Tsuruo 2003). The 
cell surface receptor for folate is inaccessible from the circulation to healthy cells owing to 
its location on the apical membrane of polarized epitheHa, but it is overexpressed on the 
surface of various cancers, including ovary, brain, kidney, breast, and lung malignancies 
(Leamon & Reddy 2004, Leamon & Low 2001). Surface plasmon resonance studies 
revealed that folate conji^ated PEGylated cyanoacrylate nanoparticles had a tenfold higher 
affinity for the folate receptor than free folate did (Stella 2000). Folate receptors are often 
organized in clusters and bind preferably to the multivalent forms of the, ligand. 
Furthermore, confocal microscopy demonstrated selective uptake and endocytosis of folate-
conjugated nanoparticles by tumor cells bearing folate receptors. Interest in exploiting folate 
receptor targeting in cancer therapy and diagnosis has rapidly increased, as attested by many 
conjugated systems, including proteins, liposomes, imaging agents, and neutron activation 
compounds (Leamon & Reddy 2004, Leamon & Low 2001, Stella et al. 2000). 
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Cieavable bond 
3. Acidified endosomes 
4. Endosomal release 
Figure 1.8 Nanoparticle based dtug detiveiy and ta^^eting using teceptof-
mediated endocytosis. The nanoparticle drug is intetnalized by tumor cells dirough 
ligand-receptor interaction. Depending on the design of the cieavable bond, the drug will 
be released intracellulady on exposure to lysosomal enzymes or lower pH (adapted 
from N i e S era /2007) . 
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3. Nanopatticle Drugs 
Nanotechnology is beginning to change the scale and methods of drug delivery (Figure 
1.9). Therapeutic and diagnostic agents can be encapsulated, covalently attached, or 
adsorbed onto nanoparticles. These approaches can easily overcome drug solubility 
issues, which have significant implications because more than 40% of active substances 
being identified through combinatorial screening programs are poorly soluble in water 
(Merisko-Liversidge et al. 2003). Conventional and most current formulations of such 
drugs are frequently plagued with problems such as poor and mconsistent bioavailability. 
The widely used attempt at enhancing solubility is to generate a salt. For non-ionizable 
compounds, micronization, soft-gel technology, co-solvents, surfactants, or complexiiig 
agents have been used (Fishman et al. 2004). Because it is faster and more cost 
effective to refomiulate the drug than to develop a new one, a technology applicable to 
poorly water-soluble drugs could make a tremendous impact. For decades, researchers 
have been developing new anticancer agents and new formulations for delivering 
chemotherapeutic drugs (Larsen et al. 2000). Paclitaxel (Taxol TM) is one of the most 
widely used anticancer drugs in the clinic. It is a microtubule-stabilizing agent that 
promotes tubulin polymerization, disrupting cell division and leading to cell death (Diaz 
et al. 2000, Nicolaou et al. 1993). It displays neoplastic activitv' against pnmarv 
epithelial ovarian carcinoma and breast, colon, and lung cancers. Because it is poorlv 
soluble in aqueous solution, the formulation available currently is Qiremophor EL 
(polyethoxylated castor oil) and ethanol (Singia et al. 2002). In a new formulation 
approach used in Abraxane TM, recently approved by the FDA to treat metastatic breast 
cancer, paclitaxel was conjugated to albumin nanoparticles (Garber 2004). The 
formulation is very effective in circumventing side effects of the highly toxic 
Qiremophor EL, which includes hypersensitivity reactions, nephrotoxicity, and 
neurotoxicity (Singia et al. 2002, Geldetfclom et al. 2001). Although the SPACR 
(secreted protein, acidic, cysteine-rich, also called osteonectin) protein is believed to 
improve albumin drug uptake, this nanoparticulate drug still exhibits significant side 
effects (see FDA-Approved Nanoparticle Drug-Abraxane). 
For enhanced tumor-specific targeting, the differences between cancerous cells and 
normal cells may be exploited. By virtue of their small size, nanoparticles entail a high 
surface area that not only paves the way for more efficient drug release but also a better 
strategy for functionalization. There is a growing body of knowledge of unique cancer 
markers, thanks to recent advances in proteomics and genomics. They form the basis of 
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complex interactions between bio-conjugated nanoparricles and cancer cells. Camer 
d e s i ^ and targeting strategies may vary according to the type, developmental stage, and 
location of cancer (Vicent 8c Duncan 2006). 
Tumor-specific enzyme 
cleavable linkage 
Anticancer agent 
Self-assembled polymer 
Covalently linked 
targeting ligand 
100 nm 
Receptor-mediated 
endocytosis 
Figure 1.9 Self-assembled polymeric nanoparticles with dual tumor-targeting and 
therapeutic functions (upper pane/) and delivery of the nanoparricie drugs by receptor-
mediated endocytosis and controlled drug release inside the cytoplasm {lower panel) 
(adapted from Nie S et al. 2007). 
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There is much synergy between imaging and nanotechnology in biomedical applications. 
Many of die principles used to t a i ^ t delivery of drugs to cancer may also be applied to 
tai^et imaging and diagnostic agents to enhance detection sensitivity in medical miaging. 
With engineered multifunctional nanoparticles (Figures 1.10), the full in mm potential of 
cancer nanotechnology in targeted drug delivery and imaging can be realized. 
Tumor-specific enzyme 
cleavabte linkage 
Polymer carrier 
Anticancer agent 
Imaging agent 
Covalently linked 
targeting ligand 
100 nm 100 nm 
Figure 1.10 Multifixnctional nanoparticles for integrated cancer imaging and therapy. A 
truly exciting feature of cancer nanotechnology is that drug delivery, treatment efficacy, 
and toxicity could be monitored by using embedded imaging agents (adapted firom Nie 
SetallWT). 
The medical application of nanotechnology (that is, 'nanomedicine') has enormous 
potential to improve healthcare, particularly in cancer (NCI Plan. 2004, Emopean 
Science Foundation. 2005, Fettati 2005). On one hand, miniaturization is creating 
devices for use as diagnostics, biosensors and imaging agents, and on the other, ever 
more sophisticated synthetic chemistry is producing nanovectors for drug detivery. The 
terminology used is often contentious and can be confusing. Ferrari recendy coined a 
useful definition of cancer nanotechnology (Fettati 2005) as "a vast and diverse array of 
devices derived from engineering, biology, physics and chemistry, including nanovectors 
for the targeted delivery of anticancer drugs and imaging contrast agents, and those 
detection systems such as nanowires and nanocantilever arrays under development for 
the early detection of precancerous and malignant lesions from biological fluids." 
Nanovectors have also been called 'nanopharmaceuticals or nanomedicines'. To 
distinguish them ftom biotech products, such as proteins and antibodies (which are also 
inherendy 2-15 nm in size), die European Science Foundation's Forward Look on 
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Nanomedicine defined nanomedicines as "nanometer size scale complex systems, 
consisting of at least two components, one of which being the active ingredient" 
(European Science Foundation. 2005). 
4. Polymer therapeutics as anticancer agents 
Natural and synthetic polymers are used widely as components of new medical devices, 
for example, as rate-controlling coatings, as hydrogels or matrices for the topical 
administration of dmgs, in tablets and capsules for oral administration and controlled 
release systems for dmgs, peptides and proteins, and as constmcts for tissue engineering. 
However, it has only been during the last decade that the first polymer-based 
therapeutics emerged as clinically accepted medicines for parenteral administration. The 
term 'polymer therapeutics' was coined to describe the biologically active polymeric 
drags (Donaruma 1974, Seymour 1991, Regelson & Parker 1986), polymer-drug 
conjugates (Duncan 1992, Duncan 2003, Kopecek et al. 2000), polymer-protein 
conjugates (Harris & Chess 2003, Pasut et al. 2004), polymeric micelles to which a 
drag is covalently bound (Yokoyama et al. 1990) and multi-component polyplexes 
(containing covalent linkers) being developed as non-viral vectors tor gene and protein 
delivery (Pack 2005, "Wagner & Kloeckner 2005). From the industnal standpoint, these 
are new chemical entities rather than conventional dmg-delivery systems or formulations 
that simply entrap, solubilize or control drt^ release without resorting to chemical 
conjugation. The distinction is between a covalently bound biologically active system, 
and one that is non-covalendy complexed or simply entrapped. 
Polymer-drug conjugates 
Biological rationale for the design of polymer-anticancer drug conjugates and methods 
for their preclinical evaluation (Kopecek et al. 2000, Duncan 2005) still hold tme 
today. The clinical aims of polymer-dmg conjugation are, to achieve improved dmg 
targeting to the tumor, to reduce dmg toxicity (by limiting access to the sites of toxicity) 
and to overcome the mechanisms of dmg resistance. First generation conjugates sought 
to improve the therapeutic index of dmgs already in routine clinical use (for example, 
doxombicin, camptothecins, paclitaxel and platinates including carboplatm and 
diaminocyclohexane (DACH)-platmates). Conjugation to hydrophilic polymeric carriers 
can also improve the water solubility of hydrophobic dmgs such as doxombicin and 
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paclitaxel, enabling easier formulation and patient administration. Almost all polymer-
drug conjiigates that have been clinically tested rely on increased tumor vascular 
permeability (EPR effect) for tumor targeting. Many preclinical studies suggest 
opportunities for the tumor-specific targeting of polymer conjugates (Duncan & Izzo 
2005, Duncan 2005) using antibodies, peptides (example, melanocyte stimulating 
hormone (QHarc et al. 1993) and other ligands (example, folate (Low & Antony 
2004); only one such targeted conjugate, HPMA copolymer-doxombicin-galactosamine 
has so far been evaluated clinically. Many polymers have been proposed as dmg carriers 
(Brocchini & Duncan 1999), but few have progressed to in liw or clinical studies. 
Problems that are prohibiting further development include inherent polymer-related 
toxicity and/or polymer-related immunogenicity (polymers, as macromolecules, can 
cause an immune response (unlike PEG), so choice of polymer should be made carefully 
(Rihova 1996); inadequate drug loading or inappropriate choice of drug (usually potency 
too low); and the use of unsuitable polymer- drug linkers - being either too stable 
(therefore preventing dmg liberation and access to the pharmacological tai^et), cr 
degrading too quickly in aqueous solutions leading to premature drug release. 
Design of polymer-drug conjugates 
Induction of polymer chemistry for drug conjugation (Ringsdorf 1975) and later 
demonstration of the endocytic pathway useful for lysosomotropic dmg delivery (de 
Duve et al. 1974) led to the concept of tai^etable anticancer polymer-dmg conjugates. 
Low-molecular-weight anticancer agents typically distribute randomly throughout the 
body, and this often leads to side effects. The attachment of dmgs to polymeric carriers 
can: 
• Limit cellular uptake to the endocytic route. 
• Produce long-circulating conjugates. 
i 
Most of the dose of low-molecular-weight dmg typically leaves the circulation within 
minutes, whereas a polymer conjugate will ideally circulate for several hours to facilitate 
passive tumor targeting caused by the leakiness of angiogenic tumor blood vessels by the 
enhanced permeability and retention effect (EPR effect) (Matsumura & Maeda 1986). 
Conjugates have also been synthesized to contain targeting ligands (such as antibodies, 
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peptides and sugars) with the aim of further promoting increased (building on the EPR 
effect) tumor targeting by receptor-mediated delivery (Duncan 1992). 
Several features are needed for the effective design of polymer-drug conjugates: 
• The polymer must be non-toxic and non-immunogenic. It must also be suitable 
for industrial-scale manufacture. Polymer molecular weight should be high 
enough to ensure long circulation, but for non-biodegradable polymeric carriers 
this moleciJar weight (Mw) must be less than 40,000 g mol"' to enable the renal 
elimination of the carrier following dmg delivery. Therefore, the optimum 
(usually Mw 30,000-100,000 g mol"') must be tailored to suit the particular 
polymer being used. 
• The polymer must be able to carry an adequate dmg payload in relation to its 
potency. 
• The polymer-dmg linker must be stable during transport to the tumor, but able 
to release the dmg at an optimum rate on anival uithin tumor cells. 
• If the dmg exerts its effects through an intracellular pharmacological receptor, 
access to the correct intracellular compartment is essential. Peptidvl and ester 
polymer-dmg linkers have been widely used. In particular, peptide sequences are 
designed that undergo cleavage by the lysosomal thiol-dependent protease 
cathepsin B (Duncan et al. 1983), but often pH-sensitive ds-aconityl, hydrazone 
and acetal linkages have also been used which are hydrolysed within endosomal 
and lysosomal vesicles because of the local acidic pH (6.5-4.0). The ideal rate of 
release will vary according to the mechanism of action of the drug beiiig 
delivered. Typically, conjugates containing doxombicin linked by Gly-Phe-Leu-
Gly release the drug payload over 24-48 hr. 
• The intracellular delivery and transfer of a dmg out of the endosomal or 
lysosomal compartment is in many cases not only essential for therapeutic 
activity (Lloyd 2001), it also provides the opportunity to bypass mechanisms of 
dmg resistance that are reliant on membrane efflux pumps such as p-glycoprotein 
(Minko et al. 1998). The limitauon of polymer Mw to <I00,000 g mol"' ensures 
that the conjugate will be small enough to extravasate easily into the tumor, and 
will enable endocytic internalization by all types of mmor cells. 
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2.3 Mechanism of action of nanopaiticles 
a. Drug that is covalently bound by a linker that is stable in the circulation is lai^ely 
prevented from accessing normal tissues (including sites of potential toxicitv), 
and bio-distribution is initially limited to the blood pool. 
b . The blood concentration of drug conjugate drives tumor targeting due to the 
increased permeability of angiogenic tumor vasculature (compared with normal 
vessels), providir^ the opportunity for passive targeting due to the enhanced 
permeability and retention effect (EPR effect). 
c. Through the incorporation of cell-spjecific recognition ligands it is possible to 
bring about the added benefit of receptor-mediated targeting of tumor cells. 
d. It has also been suggested that circulating low levels of conjugate (slow drug 
release) might additionally lead to immunostimulation. 
e. If the polymer-drug linker is suble in the circulation, for example, 7V-(2-hydrox 
ypropyl) methacrylamide (HPMA) copolymer-Gly-Phe-Leu-Gly-doxombicin, the 
relatively high level of renal elimination (whole body t l / 2 clearance >50% in 24 
h) compared with free drug (tl/2 clearance —50% in 4 days) can increase the 
elimination rate. 
f. On arrival in the tumor interstitium, polymer-conjugated dmg is internalized bv 
tumor cells through either fluid-phase pinocytosis (in solution), receptor-
mediated pinocytosis following non-specific membrane binding (due to 
hydrophobic or charge interactions) or ligand-receptor docking. Depending on 
the linkers used, the drug will usually be released intracellularly on exposure to 
lysosomal enzymes (for example, Gly-Phe-Leu-Gly and pol)^lutamic acid (PGA) 
are cleaved by cathepsin B) or lower pH (for example, a hydrazone linker are 
degraded in endosomes and lysosomes (pH 6.5- <4.0). 
The active or passive transport of dmgs such as doxorubicin and paclitaxel out of 
these vesicular compartments enstires exposure to their pharmacological targets. 
Intracellular delivery can bypass mechanisms of rejsistance associated with membrane 
efflirx pumps such as p-glycoprotein. If >10-fold, EPR-mediated targeting will also 
enable the circumvention of other mechanisms of dmg resistance. Non-
biodegradable polymeric platforms must eventually be eliminated from the cell by 
exocytosis. Rapid exocytic elimination of the conjugated dmg before release would 
be detrimental and prevent access to the therapeutic target. In general, polymeric 
carriers do not access the cytosol. 
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Figure 1.11 Understandiii^ of the mechanism of action of polymer-drug 
conjugates. Hycirophilic polymer drug conjugates administered intravenously can be 
designed to remain in die circulation - dieir clearance rate depends on conjugate 
molecular weight, which governs die rate of renal elimination (adapted from Duncan R 
2006). 
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3.1 siRNA based cancer therapy 
Antisense technology has expanded to an outstanding limit since its initial discovery in 
the nematode Caenarhabdids degins (Fire et al. 1998). Soon after this, Elbashir SM et al. 
showed that double stranded interfering RNAs (siRNAs) of -21 nt in length bring about 
gene silencing in mammalian cells (Elabashir et al. 2001). Followed by discovery, 
knowledge of its mechanism of action brings new hope for therapeutic interventions of 
human diseases. The key therapeutic advantage of using RNAi lies in its ability to 
specifically and potently knock down the expression of disease-causing genes of known 
sequence. Furthermore, the relatively short turnaround time for efficacy testing of 
potential therapeutic RNAi molecules, and the fact that even newly discovered pathogens 
are theoretically amenable to rapid targeting, has caused great excitement about the 
potential of RNAi for treating a wide range of diseases. 
Gjnsisient research is going on to utilise siRNA as a therapeutic in various disease 
caused by gene disruption, results of which have spurred cautious optimism about the 
promise of RNAi-based therapies. Very first demonstration of clinical applications ot 
RNAi have been directed at the treatment oi wet, age-related macular degeneration 
(AMD) (Check et al. 2005) and respiratory syncytial virus (RSV) infection (Bitko et al. 
2005). Therapies based on RNAi are also in preclinical development for other viral 
diseases (Rossi 2006, Dykxhoom & Liebennan 2006) neurodegenerative disorders 
(Raoul et al. 2006) and cancers (Pai et al. 2006), although a number of challenges need 
to be addressed and improvements made for RNAi-based therapies to realize their fuU 
potential. A progressively more detailed understanding of the basic mechanisms of RNAi 
has been important in developing diverse RNAi effector molecules with improved le\els 
of potency and efficacy. 
For example, synthetic siRNAs and expressed short hairpin RNAs (shRN.^) 
(Amaiyguioui et al. 2005) both have specific advantages and disadvantages, which are 
important considerations when designing RNA-based therapies for a particular disease. 
In addition, although many in liw studies have shown the potential effectiveness of 
various RNAi-based strategies, other studies have highlighted challenges that arise as a 
resuk of using an endogenous cellular mechanism for therapeutic benefit. Unwanted side 
effects have included induction of type 1 interferon (IFN) responses (de Veer et al 
2005) and saturation of endogenous RNAi pathway components (Grimm et al. 2006), 
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indicating that caution is necessary when designing effector molecules for deliver)^ into 
target cells. The issue of cell-specific or tissue-specific deliver)^ is another key challenge in 
developing RNAi based therapies. Various strategies for non-viral and viral delivery of 
RNAi triggers have recently been shown to be effective in disease models, raising the 
hope that clinical studies of RNAi-based therapies will be extended to an increasing list 
of diseases in the near future (Behlke 2006). 
3.2 Mechanisms of RNAi-mediated gene silencing 
Gene silencing by RNAi is guided by two pathways: a) siRNA b) microRNAs 
(miRNAs). RNAi complements with its homologous sequence that brings about its 
translational repression and transcript degradation. RNAi also blocks gene expression by 
direct transcriptional gene silencing (TGS) in the nucleus although its mechanism of 
action is not yet clear in mammalian systems (Figure 1.12). 
a) siRNA mediated silencing; Briefly, double stranded RNA (dsRNA) is clea\'e<j 
into small interfering RNA by a complex containing Dicer, TAR RNA-binding protein 
(TRJBP) and protein activator of protein kinase PKR (PACT). Those siRNAs are loadeii 
into Ai^onaute 2 (AG02) and the RNA-induced silencing complex (RISQ. Now-
catalytic domain of AG02 recognizes target sites in mRNA and biings about its 
cleavage. siRNAs complementary to promoter regions direct transcriptional gene 
silencing in the nucleus through chromatin changes involving histone methylation; the 
precise molecular details of this pathway in mammalian cells are currently unclear. 
b) microRNA mediated silencing: As shown in figure 1.12, endogenouslv 
encoded primary microRNA transcripts (pri-miRNAs) are transcribed by RNA 
polymerase II (Pol II) and initially processed by Drosha-DGCR8 (Di George syndrome 
critical region gene 8) to generate precursor miRNAs (pre-miRNAs). These precursor 
rruRNAs are exported to the cytoplasm with the help of exportin 5 and subsequently 
bind to the Dicer-TRBP-PACT complex, which processes the pre-miRNA for loading 
into AG02 and RISC The mature miRNA recognizes target sites in the 3' untranslated 
region (3' UTR) of mRNAs to direct translational inhibition and mRNA degradation in 
processing (P)-bodies diat contain the decapping enzymes DCPl and DCP2. 
43 
Chaptetl: Review of Ihetatute 
SiRNA 
Mediated silencii^ 
microRNA 
Mediated silencing 
I 
SiRNA 
1 
"Mettiylation of "^ 
H3K9 and H3K27 
1 
DooocxS: Transcriptional , jBene silencing 
NMchw 
Cytoplasm 
dsRNA 
SiRNA 
Translational I 
,^ Bpnessiof .^^  \ ^ 
m'G" 
ORF 
mRNA mRNA 
— — AAAA m'G — — •AAAA 
3\rrR 
1 •mRNA 1^ deavage wm—I I 
m'G« 'AAAA P-body 
Figure 1.12 Mechanisms of RNA interference in manunalian cells (Adapted from 
Kim DH and Rossi JJ 2007). 
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Oiallenges of siRNA therapy 
siRNA technology has begun to be viewed as new hope for the treatment of genetic 
disorders, infections and cancer. It certainly offers potential advantages but there are 
certain issues to be addressed. One of which is "off target" effect; this is the inhibition of 
a gene, the expression of which should not be targeted, because the gene shares partial 
homology with the siRNA The inadvertent silencing of non-target genes may lead to 
problems in interpretation of data and potential toxicity. To avoid this issue, we should 
design and select target very carefully. The basic parameters for chosing siRNAs involve 
consideration of internal repeated sequences, secondary structure, GC content, base 
preference at specific positions m the sense strand, and appropriate siRNA length (19-22 
bps). To predict off-target effects for an siRNA sequence, several computer algorithms 
have been developed. For example, AsiDesigner is a freely accessible web tool 
(http://sysbio.kribb.re.kr/AsiDesigner/), which provides step-^ise off-target searching 
^ath BLAST and FASTA algorithms (Park et al. 2008). 
Another challenge facing siRNA therapy is 'immune stimulation'; this is recognition of 
an siRNA duplex by the innate immune system (de FougeroUes et al. 2007, Bumcrot 
et al. 2006). Introduction of too much siRNA activates innate immune responses. The 
immune system is probably activated via the dsRNA sensor, protein kinase K 
Inflammatory cytokines and interferons were found to be induced by activation of NF-
kB and interferon regulatory^ factors following the recognition of siRNA by to0-like 
receptor 7 (TLR7), TLR8, and TLR9 (Manques et al. 2005). Recently 21-nucleotide or 
longer siRNAs were reported to activate TLR3, a double-stranded viral RNA sensor, and 
suppress neovascularization in sequence and target-non specific manner (Kleinman et 
al 2008). 
However, it has been reported that not all siRNAs could induce immune stimulation 
(Judge et al. 2005, Homung et al. 2005) and stimulation of innate immune response is 
nucleotide sequence dependent (Judge et al. 2005). The TLRZ-mediated interferon 
alpha induction by siRNA was shown to be sequence specific (Homung et al. 2005). 
The last, but the most important, challenge in siRNA therapy is the issue of deliver)-. 
Being an RNA entity, siRNA is anionic, hydrophilic, and unable to enter cells by passive 
diffusion mechanisms. Moreover, in liio delivery of naked siRNA to appropriate disease 
sites remains a considerable hurdle owing to rapid enzymatic digestion in plasma and 
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renal elimination, limited penetration across the capillar)^ endothelium, and inefficient 
uptake by tissue cells (Bumcrot et al. 2006). To overcome these difficulties, the 
development of effective in liw delivery^ systems is essential. 
3.4 siRNA deliveiy systems for in vivo application 
Keeping in view the hurdles that affect SLRNA delivery researchers have developed many 
vectors for in utro delivery of siRNA but still we need to come up with a suitable delivery 
vector for in uw applications (Bumcrot et al. 2006). Currently, siRNAs in clinical trials 
are directly administered to local target sites such as the eye and lung, thereby a\'oiding 
the complexity of systemic delivery. However, it is necessary to introduce siRNA by a 
systemic route to treat most cancers and other diseases. 
The optimal in liw systemic delivery systems for sLRNA should be biocompatible, 
biodegradable, and non-immunogenic. Second, the systems should provide efficient 
delivery of SLRNA into target ceUs or tissues with protection of the active double-
stranded siRNA products from attack by serum nucleases. Next, the delivery systems 
must provide target tissue-specific distnbution after systemic administration, avoiding 
rapid hepatic or renal clearance. Finally, after delivery into taiget cells via endoc}tosis, the 
systems should promote the endosomal release of stRNA into the cytoplasm, allowing 
the interaction of siRNA with the endogenous RISC (Juliano et al. 2008, Aigner2007). 
To confer dmg-like properties such as stability, cellular delivery, and tissue bioavailabiliry 
to siRNAs, various strategies that range from chemical modification of stRNA to design 
of different non-viral vectors have been developed and validated. 
1. Chemical modification 
To enhance the stability of siRNA for prolonged circulation in vivo, chemical 
modification of siRNA has been attempted. Various positions within the siRNA duplex 
have been chemically replaced or modified to provide nuclease resistance. One of the 
common approaches is replacement of the phosphodiester (PO4) group with 
phosphothioate (PS) at the 3'-end. Moreover, the introduction of an O-methyl group (2-
OMe), a fluoro (2'-F) group, or a 2-methoxyeth)d (2'-0-M0E) group resuked in 
prolonged half-lives and RNAi activities in culmred cells and plasma (Chiu et al. 2003, 
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Hatborth et al. 2003, Czaudema et al. 2003, Braasch et al 2003, Layzer et al. 2004). 
Modification of siRNA using small molecules such as 2,4-dinitrophenol (DNP) was 
found to increase not only nuclease resistance but also the membrane permeability of 
siRNA (liao & "Wang 2005) Indeed, boranophosphonate siRNA showed a better 
resistance to nuclease degradation than did an unmodified siRNA but 
boranophosphonate modification at the central position of the antisense strand reduced 
RNAi activity (Hall et al. 2004). In addition, the degradation of a modified siRNA into 
molecules not natural to the body may give rise to the fear that metabolites of such an 
siRNA maybe unsafe. 
2. Lipid-based siRNA delivery 
Various lipid-based delivery systems have been developed for in uw application of 
siRNA Lipid-based systems mclude liposomes, micelles, emulsions, and solid lipid 
nanoparticles. For the delivery of siRNA using lipid-based systems, lipid composition, 
dmg-to lipid ratio, particle size, and the manufacturing process should be optimized. 
Among synthetic delivery s\-stems for SLRNA cationic liposomes have emei^ed as one ot 
the most attractive vehicles o'^ing to the simple manner in which such liposomes form 
complexes with negatively charged siRNA their high transfection efficiency, their 
enhanced pharmacokinetic properties, and their relatively low toxicity and 
immunogenicity. Moreover, cationic liposomes can protect siRNA from enzymatic 
degradation, and provide reduced siRNA renal clearance. 
3. Polyme r- me diate d s iRNA de live ry 
Polymer-based delivery systems have been extensively used for plasmid DNA and more 
recently for siRNA As with lipid-based delivery systems, polymeric delivery of siRNA 
usually involves a cationic moiety as a core component. The development since 1990 of 
cationic polymers for delivery of plasmid DNA has resulted in the accumulation of much 
I 
relevant information. siRNA differs from plasmid DNA in molecular weight, charge 
ratio, stability, and method of action. However, as both are nucleic acids, siRNA and 
plasmid DNA share a number of characteristics relevant to in vivo delivery. Accordingl)', 
polymer-mediated DNA delivery systems would provide a lot of informative knowledge 
for the development of polymer-based siRNA therapeutics (Gaiy et al. 2007). 
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Chapter 2: Anticancer efficacy of perillyl alcohol-bearing PLGAmlcroparticles 
Cytotoxicity and other related side effects are the most serious problems associated v,ith 
the currently available anticancer drugs. Other limitations include widespread systemic 
distribution and rapid elimination of the administered anticancer drugs from the host 
body. A worldwide search therefore continues for anticancer drugs that are more potent, 
less toxic, and manifest minimum untoward effects to the host. Several plant deri\ed 
compounds have been reported to possess strong anticancer properties and have been 
shown to delay, inhibit, or reverse cancerous growth in an effective manner. For 
example, perillyl alcohol (POH), a plant-based compound, has been reported to possess 
strong ami-cytotoxic properties against several types of cancer including those of breast, 
pancreatic, and liver (Haag & Gould 1994, Stark et al. 1995). POH is a monoterpene 
and constituent of essential oils from a number of plants; namely, perilla {Perillafnaescers), 
lavendin, peppermint, ginger grass, savin, caraway, and celery seeds (Figure 2.1). 
CH2OH 
H3C CH2 
Figure 2.1 Chemical structure of perillyl alcohol. 
Before translating the suitability of a novel compound like POH as a potential anticancer 
agent in the clinical setting, it is desirable to address some of the associated issues like 
that of its solubility, palatability, and sustained/controlled release in systemic circulation. 
This requires designing of a suitable drug-delivery system that can release the drug 
gradually over a long period of time and, in turn, facilitate its uptake by cancer cells and 
thereby helps in increasing the efficacy of the entrapped drug. Polymeric micropanicles 
offer a promising technology in this regard. 
Encapsulation of drugs in the core of microparticles have been shown not only to 
protect them from the external environment enroute, but also help in increasing their 
plasma half-lives in systemic circulation thereby facilitating the attainment of optimum 
drug availability at the desired target (MuHeret al. 2002, Spiclin et al. 2003, Fang et al. 
2006). 
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To develop promising and effective formulations of anticancer compounds, various 
polymeric nutrices have been investigated and their efficacies worked out.5-10 Drug 
delivery systems, such as nanoparticle (Muller et al. 2002), microemulsion (Spiclin et 
al 2003), nanoemulsion (Fang et al. 2006), and liposome-based delivery systems (Betz 
et al. 2005, Kirjavainen et al. 1999, Khan et al. 2007), have been shown to enhance the 
efficacy of various compounds on systemic as well as topical applications. Among 
various drug-carrier systems, poly-lactic glycolic acid (PLGA) matrices have been 
reported to be nontoxic, biodegradable, and shown to release the entrapped drug 
gradually over a long duration (Nair & Laurencin, 2007). 
In the present study, POH-bearing PLGA microparticles were prepared and their 
efficacy against the skin epidermoid cancer cell line (A253) was evaluated. In addition, 
potential of POH-bearing PLGA microparticles was evaluated in treatment of di-methyi 
benzo anthracene (DMBA)-induced tumors in Swiss albino mice. 
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All reagents used in the study were of highest purity available. PLGA, poly vinyl alcohol 
(PVA), and POH were purchased from Sigma Chemical Company (St Louis, MO). 
Dichloromethane (DCM) was of analytical grade of purity and procured locally. Anti-p53 
mutant, anti-p53 wild-type (wt), anti-p21/wafl, anti-tubulin and anti-^-actin antibodies 
were purchased fromBD Biosciences (San Diego, CA). 
Preparation of POH-loaded PLGA microparticles 
Microparticles used in the present study were prepared by oil-in-water-based emulsion 
solvent evaporation technique using the published protocol as standardized in our 
laboratory (Jeffery et al. 1993, Farazuddin et al. 2009). Briefly, a known quantity of 
POH (30 rr^ dissolved in minimum volume of methanol), mixed with PLGA solution 
(190 rr^ PLGA dissolved in 1.0 mL DCM), and sonicated in a bath-type sonicator to 
form the primary emulsion. The primary emulsion was mixed with 100 mL of 10% PVA 
(w/v) and homogenized using a Silverson L4RT homogenizer (Silverson Machines, East 
Longmeadow, MA). The resulting oil-in-water emulsion was stirred at 25°C for 18 houi^ 
to allow solvent evaporation and formation of POH-entrapped micropanicles. The 
microparticles were centrifuged at 10,000 x g for 10 minutes and thoroughly washed "w-ith 
phosphate buffered saUne (PBS) (0.15 M NaCl containing 20 mM sodium phosphate, pPI 
7.4) to remove siuface adsorbed drug. The microformulation was lyophilized and finallv 
stored at 4°C until further use. 
Entrapment efficiency of POH in microparticles 
Entrapment of P O H in microparticles was assessed by dissolving an aliquot of the 
microparticles in 0.1 N NaOH followed by analysis of POH content by high-
performance liquid chromatography (HPLQ following the published procedure (Tao & 
Pereira, 1998). Briefly, 10 mg freeze-dried microparticles were dissolved in 1.0 mL of 0.1 
N N a O H The solution was vortexed for 10 minutes followed by centrifugation for 5 
minutes at 9168 x g at 25°C An aliquot (100 [iL] of supernatant was mixed with 900 \iL 
methanol. The suitable aliquots, of the resultant homogenate solution, were analy^sed by 
reversed phase HPLC using a Symmetry® G18 column (3.9 mm x 150 mm). The 
solvent system used was isocratic methanol-water (72:28, v/v). Entrapment of POH was 
calculated with the help of calibration curve using the pure drug plotted at 220 nm The 
percentage entrapment efficiency (% EE) was calculated with the following formula. 
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% EE = (amount of POH entrapped)/(total amount of POH used in the beginning) x 100. 
Scanning electron microscopy of the mictoparticles 
Scanning electron microscopy (SEM) was performed to characterize the size and surface 
morphology of POH-loaded microparticles using scanning electron microscope (Zeiss 
EVO 40; Qr l Zeiss SMT AG, Oberkochen, Germany). The lyophilized preparation of 
POH-loaded microparticles was suspended in 20 mM PBS pH 7.4, and a drop of the 
formulation was mounted on clear glass stub, air dried, and coated with gold-palladium 
alloy usiQg a sputter coater. An accelerating voltage of 20.00 kV was used for imaging. 
Determination of ^-potential 
C-potential of the PLGA microparticles was determined using DTS software (Malvem 
Instruments Ltd, Worcestershire, UK) based on M3-PALS technology. The formulation 
was lyophilized in a 2.0 mL microfuge tube, and the samples were reconstituted in 2!0 
mA'I phosphate buffer, pH 7.4. This dispersion was then rapidly dispensed to a 
electrophoresis cell to measure the electrophoretic mobOit}', and ^potential xalues were 
calculated. The experiment was repeated three times, and the average ^-potential v^ t^h 
standard deviation was calculated. 
In litro release kinetics of active POH from PLGAmicroparticles 
To assess the release kinetics of POH from PLGA microparticles, mukiple weighed 
akquots of the microparticles were dispensed in separate microvials. To each vial, 1.0 mL 
of 20 mM sterile PBS was added, followed by incubation at 37°C. Aliquots (100 \sl) of 
supematant were removed after centrifugation at 9168 x g for 10 minutes and anal>7;ed 
for the POH content. 
Toxicity tests for POH-bearing PLGA microfomiulation 
A new formulation of a given drug molecule has to be tested for any inherent toxicirv 
before being examined for its efficacy. To settle this issue, toxicity of the in-house 
prepared formulation was tested both in vitro and in vivo. Preliminary acute drt^ toxicit}' 
was based on in vitro erydirocyte lysis test, wherein hemoglobin, released as a result ol 
membrane leakage or disruption catised by exposure to low doses of the dmg, is 
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measured (Khan et al. 2002). Briefly, fresh blood was obtained from a healthy rabbit 
and collected in anticoagulant solution (ethylenediaminetetraacetic acid), followed by 
centrifugation at 1000 x g for 10 minutes at 4°C Buffy coat as well as plasma was 
discarded. The washed erythrocytes were diluted with isotonic buffer (20 mM PBS), and 
50% hematocrit was prepared. To study the extent of hemolysis, the suspension of red 
blood cells (RBCs) was incubated with 1.0 mL of free form as well as POH encapsulated 
in PLGA microparticles (10 mg/mL) at 37°C for 1 hour. Free POH was dissolved in 50 
I^ L of dimeth)^ sulfoxide (DMSO), and finally volume was made up to 1.0 mL with PBS 
(final 5% DMSO). After 1 hour, the reaction mixture was centrifuged at 1500 x g, and 
supernatant was collected and analyzed by ultraviolet-visible spectroscopy (Xmax = 576 
nm) for released hemoglobin. The percentage hemolysis was determined by the following 
equation: 
[(AbsT - AbsC)/Absl00% - AbsC)] x 100, 
where AbsT is the absorbance of the supematant from samples incubated with the drugs, 
AbsC is the absorbance of the supematant from controls (PBS), and Absl00% is die 
absorbance of the supematant of controls incubated in the presence of 1% Tnton® X-
100, which causes complete lysis of RBQ (total hemolysis). 
Hepatic and renal toxicities were monitored by applying multidose regimen (total seven 
doses, at altemate days) to determine biochemical profiles of semm creatinine and 
alkaline phosphatase (ALP). The blood was collected by retro-orbital puncture from the 
mice of different groups after the last administered dosage. The blood was allowed lo 
clot at room temperature, and serum was separated for investigation of creatinine and 
ALP as per respective guide provided by the manufacturer. 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetiazolium bromide) assay 
Epidermoid carcinoma cell line A253 (ATCC HTB-41TM) was purchased from ATCC 
(Manassas, VA) and maintained in Roswell Park Memorial Institute (RPM) 1640 culture 
medium supplemented with 10% heat-inactivated fetal calf semm. To perform MTT 
assay, 5 x lO"* cells were transferred to each well of a 96-well plate. The plate was 
incubated for 24 hours, and then increasmg concentrations (0-60 txg/mL) of POH were 
added to each well, three wells received medium only with no POH and served as 
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control. The plate was incubated for 72 hours, and cell proliferation was measured by 
adding 20 fxL MTT dye (5 mg/mL in PBS) per well. After furdier incubation for another 
4 hours at 37°C in a humidified chamber with 5% C02, the formazan crystals formed 
due to reduction of dye by viable cells in each well were dissolved in 150 i^L DMSO, and 
optical density (OD) was read at 620 nm in a SpectraMax M2 plate reader (Molecular 
i 
Devices, Sunnyvale, CA). 
Effect of POH-PLGA-micnoparticles in induction of apoptosis in the human 
epidennoid cancer cell line 
To examine the in vitro inhibitory effect of POH-bearing PLGA microparticles, the 
microformulation as well as free form drug was incubated with A253 ceOs (1 x 10^  cells) 
for 12 and 24 hours. After incubation, the cells were scraped, centrifuged, anc washed 
with RPMI medium and lysed with TNN lysis buffer. The lysate was subjectea to 12% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis, and gels were electroblotted 
on polyvinylidine fluoride (PVDF) membrane follo"w.Tng published protocol (Towbin et 
al. 1979). 
Animals 
Female Swiss albino mice of weight 20+2 g were obtained from the institute s animal 
house facility. The animals were housed in poly propylene cages on wood powder 
bedding in an air-conditioned ambience. Animals were quarantined on equal light/dark 
cycles (12/12 hour) and were kept on a pellet diet (Ashirwad, Qiandigarh, India) and 
water ad lihiuon Animals were examined for their mortality and morbidity pnor to 
commencement of the study, and only healthy animals were included in the experiments. 
The techniques used for administration of various formulations as well as sacrifice of the 
animals were strictly performed following mandates approved by the animal ethics 
committee (GDmmittee for the Purpose of Control and Supervision of Experiments on 
Animals, Govemment of India). 
Treatments 
Animals in the resting phase of hair cycle were used in the study. The interscapular 
regions (over an area of 2 cm^ of the experimental animals were shaven using non 
53 
Chapter 2: Anticancer efficacy of perillyl alcohol-bearing PLGAmicroparticles 
lubricated electric clippers. The mouse skin tumors were induced by using DMBA as 
carcinogen following the procedure standardized in our laboratory (Khan et al. 2007). 
The skin of the shaven dorsal portion of the mice was exposed to DMBA (52 fxg in 200 
nL acetone) that was applied topically three times a week for 12 weeks. Animals were 
routinely examined for gross morphological changes on skin and development of 
tumors. It has been reported that POH at 10 mM concentration does not cause toxicity 
in a mice model (Barthelman et al. 1997). This fact was kept in mind when selecting 
specific dosage regimens of various cream-based POH formulations. The formulations 
of POH were appEed daily with cream base for a period of 7 days after induction of 
papilloma, with a dose of 10 mM POH in 500 fxL cream base per animal. Animals were 
observed for 1 month to examine the effect of various formulations. The animals were 
divided into the following groups; each consisting of 15 animals: 
Group I untreated control (DMBA applied, followed by treatment with cream base 
only); 
Group II sham PLGA microparticles; 
Group III control (heakhy animals); 
Group IV POH (free form); 
Group V POH-bearing PLGA microparticles. 
Tumor measurement 
Tumor measurement was carried out after 1 month of last dosage application of various 
POH-based formulations. The diameters of the tumors were measured using a Vemier 
Caliper, and the tumor volume was determined using the following formula: 
V = D X d2 X n/6, 
where V = tumor volume, D = biggest dimension, and d = smallest dimension. 
Histopathological studies 
Animals were sacrificed and their excised papillomas were immersion fixed in 10% 
formalin. Next, the tissue blocks of 3 x 6 x 5 mm-* dimensions were processed for 
paraffin embedding. Thick sections (10 micrometer) were cut with rotary microtome and 
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stained with H and E stain. Observations were made under light microscope (Olympus-
BX 40-Japan), representative photomicrographs with final 
used for comparative study. 
Preparation of whole ceil fraction 
i 
The skin/tumor tissues were removed from experimental mic&>*iiffi^jjaip^calpel 
blades. The tissue samples were placed on ice, and fat was scraped off before further 
processing. The samples were homogenized in the presence of protease inhibitor 
cocktail, and the whole cell fraction was prepared according to the method published 
elsewhere (Serpi et al. 1999). 
Western blotting 
The tissue homogenate was analyzed for the presence of various apoptotic factors by 
Westem blotting (Towbin et al. 1979). Briefly, the protein content of the homogenate 
was determined by LO-^TV et al method using bovine serum albumin as a standard 
(Kocbek et al. 2007). The homogenate (30 ^tg/well) was subjected to 10%SDS-PAGE 
under denaturing conditions. The gels were electroblotted onto P\T)F membranes, 
blocked ovemight wih 5% non-fat dry milk and probed with appropriate antibodies at 
the dilutions recommended by the suppliers. To quantify equal loading, membranes were 
re-probed with a-tubulin antibody to determine housekeeping protein tubulin. 
Statistical analysis 
One-way analysis of variance was used for comparing the mean values of tumor volume 
between various groups after ascertaining the homogeneity of variance between 
treatments. Post-hoc analysis for comparing the two groups was done using the least 
statistical difference technique. The Kaplan-Meier analysis was used to determine survival 
of tumor-free animals, and differences among various experimental groups were analyzed 
by log-rank test. 
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Entrapment efficiency, size, and ^-potential of PLGA microparticles 
Various PLGA-based microparticle formulations have been widely used for the deliver)' 
of antibiotics as well as anticancer drugs to accomplish sustained release of the entrapped 
drugs (Tao & Pereip 1998, Kocbek et al. 2007). The in-house developed PLGA 
microparticles had entrapment efficiency of 42.4+3.5, and size \^ ^s 768+215 nm, as 
revealed by SEM and Nanophox (Sympatec GmbH, Qausthal-Zellerfeld, Germany) size 
analyzer (Figure 2.2A and B). As (-potential acquired by a small sized particle regulates 
its half-life in vitro as well as in vivo, it was considered important to determine -^
potential of the in-hotise prepared microparticles. The POH-PLGA microparticles used 
in the present study had a (-potential of -7.6+0.8 mV. 
In vitro release kinetics of POH-loaded PLGAmicroparticles 
In vitro release kinetics of POH-loaded PLGA microparticles was studied at 37°C in 
PBS, pH 7.4. POH-PLGA microparticles showed sustained release, v,ith only 12% of the 
entrapped drug leaking out in the initial 18 hours. In the next 12 hours, around 17% of 
the total drug was released. PLGA microparticles showed an inkial burst release pattern 
followed by sustained release kinetics for extended time period. In the present study, 
PLGA microparticles were fotind releasing 22% in the initial 72 hours with an overall 
total 30% release in 168 hours (Figure 2.2C). 
In vitro and in vivo toxicity of POH-based PLGA microparticle formulation 
Before determining the efficacy of any formulation, k is desirable to assess its intrinsic 
toxicity. With this aim, VOVi bearing PLGA microparticle (in-house prepared) toxicity 
was evaluated, and k was found that POH-bearing PLGA microparticles had induced 
relatively less percent RBC lysis than free form of the drug (Figure 2.3). Sham PLGA 
also induced very negligible lysis. 
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Figure 2.2 (A) Scanning electron microscopy image of POH-loaded PLGA 
tnicroparticles. (B) Corresponding particle analyzer data as obtained by Nanophox 
particle siae analyzer. (C) In vitro release kinetics of POH from PLGA 
tnicroparticles. Release kinetics of POH-PLGA micropartide formulation demonstrates 
~30% release of POH from the copolymer at 168 hours, when formulation was 
dispersed in 20 mM phosphate buffer, pH 7.4 at 37°C. Data are means ± standard 
deviations of three independent experimental values. 
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Figure 2 J Etythfocyte lysis test: In vitro toxicity was measured by erythrocyte 
lysis caused by diflferent POH formulations. Haemolysis test was perfonned as 
described in the Materials and methods section. Data represented here are means of 
three different experiments ± standard deviations. 
In another set of experiments, animals treated with multiple dosages of POH-bearing 
PLGA microparticies were analyzed for liver as well as renal function test parameters to 
evaluate in vivo toxicity. As shown in Table 2.1, POH-bearing PLGA microparticies had 
comparatively low levels of ALP and creatinine than the free form of die drug. The 
results established that POH-bearing PLGA microparticies did not have any in vitro and 
in Arivo toxicity and are safe to use. 
Table 2.1 Concentrations of creatinine and ALP in plasma of animals treated with 
POH-bearing PLGA microparticle formulation 
Groups Creatinine (mg %) ALP ( lU/L) 
Control 
Sham PLGA microparticies 
POH (free form) 
POH-PLGA microparticies 
0.32 ± 0.052 
0.28 ± 0.034 
0.35 ± 0.038 
0.31 ±0.011 
32.46 ± 2.12 
36.88 ± 3.41 
44.28 ± 2.32 
34.25 ± 2.14 
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Cytotoxic effect of POH-bearing PLGA microparticles 
The cytotoxic effect of POH formulations against epidermoid cancer cells was studied 
using MTT assay as shown in Figure 2,4. The data shows that the cytotoxic effect of 
POH was significant on epidermoid cancer cells at a concentration of 25 [J.g/mL and 
resulted in killing of about 30% of the cell population. Nanoparticles are endocytosed by 
cells faster (Kocbek et al. 2007), enabling high pa}4oad of drug molecules, and exhibit 
more cytotoxic effect. With this hypothesis, the differential cytotoxicity of free and 
PLGA microparucle-encapsulated POH at its half maximal inhibitory concentration 
(IC50) was investigated. As shown in Figure 2.5, free POH caused 50% cell death, 
whereas it increased to ~65% in the POH-PLGA microparticle-treated group in 48 
hours incubation (POH-PLGA-microparticle zersus free POtUpO.OOl). 
In addition, the time-dependent efficacy of POH-bearing microparticles on epidermoid 
cancer cell system was examined. As shown in Figure 2.6A, POH-PLGA microparticles 
enhanced the expression of p21/wafl and bax at 12 hours post-incubation, whereas 
POH in free form was not very effective. Similarly, 24 hours post-incubation, the 
expression of p21/wafl in cells treated -w-ith POH-PLGA microparticles increased 
further, while the free form dmg was not found to be effective (Figure 2.6B). ITie 
results clearly suggest that microparticle encapsulated POH is delivered efficiently to the 
cancer cells and can easily modulate various apoptotic factors and eventually results in 
apoptosis of the cancer cells. 
Effect of POH-PLGA microparticles on regression of tumors and survival of 
animals 
After establishing anticancer efficacy of inhouse-prepared microparticles against cancer 
cells in vitro, the present smdy was extended in ziw using a mouse model of skiji 
carcinoma. For this purpose, regression in the volume of DMBA-induced tumors was 
measured after treatment with various POH formulations. As shown in Figure 2.7, the 
percent regression was much higher in the POH-PLGA microparticle-treated group as 
compared with diose receiving the free form of the drug (POH-PLGA-microparticle 
lersus free POH pO.OOl). The treatment with microparticle-based POH formulation 
resulted in 80% tumor regression, while the free form of dmg was able to regress tumor 
by 65% only. The sham microparticles were devoid of any significant anticancer activity. 
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Figure 2.4 In vitto cytotoxicity of petillyl alcohol against A253 ceU line as revealed 
by MTT assay. MTT assay was performed as described in the Materials and methods 
section. Data represented here are means of three different experiments ± standard 
deviations. 
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Figure 2.5 Detemunation of differential cytotoxicity of various formuIatioiK of 
POH using MTT assay. Cells were incubated with various formulations of POH for 
48 hours. The percentage cell viability was measured with MTT assay as described in the 
Materials and methods section. Data represented here are means of three different 
experiments ± standard deviations (POH-PLGA microparticle versus free form POH 
p<o.m\). 
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Figure 2.6 Effect of POH-bearing formulations on expression of pro-apoptotic 
molecules. A253 cancer cells were treated with POH-bearing microfotmulations for 
different time periods, and cell lysates were used to examine the expression of apoptoric 
molecules. (A) Expression profile of apoptoric factors at 12 hours post-incubarion. (B) 
Expression profile of apoptoric factors at 24 hours post-incubarion. 
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POH-PlGA-microparticle POH (Free form) 
Figure 2.7 Chemothetapeutic effect of two different fotmulatioiis of POH in 
regression of tumors in treated animals. Percentage regression was calculated to 
analyze the most effective formulation of POH. It was assessed by measurii^ the size 
with Vernier calipers, and tumor volume was calculated as given in the Materials and 
methods section (POH PLGA microparticles versus free form POH; p<0.001). Sham-
PLGA microparticles behaved as control 
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Next, the efficacy of POH-PLGA microparticles was assessed in terms of the survival of 
treated animals. Survival graph shows the augmentation of anticancer efficacy of PLGA-
encapsukted POH microparticles as well as free form POH against DMBA-induced 
tumorc^nesis at different time points. POH-encapsulated PLGA microparticles showed 
80% survival, whereas the group receiving free form of POH resulted in only 40% 
survival in 13 weeks (POH-PLGA microparticles versus free POH;/)<0.05). None of the 
animals survived beyond 12 weeks in the control group that was treated with cream base 
only {p<O.OT) (Figure 2.8). 
• POH-PLG A-microparticles 
• Untreated control 
•POH (Free form) 
•Sham PLGA-microparticles 
Figure 2.8 Eflfect of POH-bearing PLGA formulatiofis on survival of DMBA-
induced skin papilloma-carrying animals. Kaplan-Meier graph shows the efficacy of 
various POH formulations in terms of percentage survival after treatment at different 
time intervals. The study was continued for a period of 13 weeks as described in the 
Materials and methods section (POH-PLGA microparticles versus free form POH; 
p<0.05). 
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Histopathological analysis 
For histopathological studies, skin tissue samples were isolated from animals of various 
groups and analyzed following the protocol described in Materials and methods. 
Hstopathological smdies of turriors identified papillomas in various groups. However, 
the relative frequency of the individual tumor types differed among animals receiving 
different treatments. In the skin of healthy animals, there were only a few cell layers thick 
keratinocytes with mild keratin and pilosebaceous units (Figure 2.9A), whereas mice 
treated with DMBA followed by no POH treatment (positive control) had obvious 
profuse papillomatous growth with complex fibrovascular core, prominent acanthosis 
and keratin perl (Figure 2.9B). On the other hand, in the free POH treated group, a 
laige amount of keratin and marked acanthosis was visible as depicted in Figure 2.9C, 
while hyperkeratosis, only mild acanthosis, and thin but long papillarv grouth v^as 
observed in animals treated -^ith POH-PLGA microparticles (Figure 2.9D). 
Western blot analysis 
DMBA is generated from incomplete combustion of various organic substances. Ii: is 
cytotoxic, muugenic, and inflicts carcinogenic effects in humans and animal models 
(Guerin 1978, Dipple et al. 1984). DMBA induces skin papillomas in animal models bv 
upregulating p53 mutant in cancer cells. As shown in Figure 2.10, POH-PLGA 
microparticles downregulate p53-mutant expression significantly when compared wth 
free form of POH. Western blot analysis was also performed to assess expression of 
p53wt and p21/wafl. POH-PLGA microparticles showedsignificant upregulation of 
p53wt and p21/wafl expression in comparison with free form POH (POH-PLCiA 
microparticles wrsus free POH;/7<D.05). 
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Figure 2.9 Photomictographs of hematoxyiin/eositi-stained sections, showing: 
(A) normal smooth skin of healthy animals with keratinocytes of only a few cell layers 
thick, mild keratin, and pilosebaceous units; (B) the positive control (DMBA treated 
animals followed by no POH treatment) has profuse papillomatous growth with complex 
fibtovascular core, prominent acandiosis, and keratin perl; (C) treatment with €ree form 
of POH resulted in large amount of keratin, and marked acanthosis; while (D) the 
treatment with PLGA microsphere encapsulated POH resulted in hyperkeratosis, 
mild acanthosis, and thin but long papillary growth. Magnification lOOx. 
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Figure 2.10 Effect of different POH-bcating formulations on the expression of 
different apoptosis-tegidating molecules in treated animals. Skin papilloma cell 
lysates were prepared as described in the Materials and methods section. Cell lysate was 
resolved and analyzed using SDS-PAGE. To ensure equal loading, membranes were re-
probed for the presence of tubulin, a housekeeping protein, using a-tubulin antibody. 
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Cell-cycle progression in eukaryotes is regulated by several key factors that determine 
whether the cell will re-enter the cycle, withdraw from it, or undergo differentiation. A 
slight deviation from the normal course may result in uncontrolled proliferation of the 
cells that eventually form the basis of cell transformation. In general, malignant sute is 
preceded by several discernible stages, including initiation of DNA damage followed by 
i 
tumor promotion both in vivo and cancer cells grov^ing in vitro. 
A large number of phytochemicals have been reported to prevent or arrest uncontrolled 
growth of cells through a variety of operative mechanisms. Current global focus is on 
natural products as a means to control various types of cancers. Some plant-based 
products possess strong antioxidant properties and have the potential to control or even 
reverse the process of carcinogenesis and emei^e as potential altematives to 
chemotherapeutic anticancer agents (Reddy et al. 2003). However, before developing 
such potential phytochemicals as prospective therapeutic agents, certain challenges such 
as palatability, poor solubility, and other related problems have to be addressed. Some of 
these can be generally circumvented through the use of an appropriate delivery svstem 
that has potential to modify the pharmacokinetics of the drug and facilitate its controlled 
and even preferential release at the desired tumor site. 
POH, a dietary constituent and a mono-terpene isolated from cherries, had been used 
widely as an anticancer agent against various types of cancer in animal models (Kelloff et 
al. 1996, Broitman et al. 1996, Lantry et al. 1997). POH is known to arrest cells in 
GO/Gl phase and induce apoptosis (Clark et al. 2007). Although P O H is a very 
effective chemotherapeutic agent, its anticancer properties have not been explored 
completely. In fact, certain intrinsic properties of POH such as small size, poor solubility 
in aqueous solution, and bioavailability restrict attainment of its effective concentration at 
the tai^eted site and thus limit its application in cancer treatment. Earlier studies suggest 
that localized delivery at the targeted site could be enhanced significantly by the use of 
microparticle^ based drug delivery and eventually can be successfuOy employed in tumor 
therapy (Vicent & Duncan 2006, Nie et al. 2007). It has recently been demonstrated 
that naturally occurring phytochemicals can be encapsulated, covalently attached, and 
adsorbed onto microparticles in order to surmount drug-solubility problems (Khan et al. 
2007, Alam et al. 2009, Alam et al. 2010). The constituents of the microparticle-based 
delivery system can also facilitate co-solubilization of the compotind/drug in question. 
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This approach has significant implication in cancer therapeutics because more than 
nearly half of the phytochemicals showing anticancer activity have solubility constraints 
(Merisko-Livereidge et al 2003). Nanosize range of the microparticles entails a high 
surface area that not only provides sustained drug release but also provides a useful 
strategy for their functionalization. The present study focuses on development and 
i 
characterization of various POH-bearing microparticle formulations and their evaluation 
in chemotherapy against DMBA-induced skin papilloma in Swiss albino mice. 
The POH-bearing PLGA micropardcle formulation was characterized for sizing using 
electron microscopy, and its surface charge properties were assessed on the basis of t-
potential. The biophysical properties of the novel formulation were also assessed. 
Further, in vitro andcancer efficacy of PLGA based POH formulation was exainined 
against human epidermoid cancer cell line (A253). Finally, the in vivo therapeutic 
potential of POH-PLGA microparticle formulations was evaluated on the basis of tumor 
size regression, survival, histology, and expression profiles of various apoptotic 
molecules. 
To optimize the size and loading efficiency of the active components, a senes ot PLGA-
based microparticles with varying compositions were prepared. The size of the inliouse 
prepared microparticles was standardized by incorporating PLGA of various molec ular-
masses. Further, the entrapment efficiency at various added weight percentage values of 
POH to PLGA was examined. It was found that 50%-70% weight of POH to that of 
PLGA leads to entrapment efficiency of around 42.4+3.5% with the size of prepared 
microparticles in the range of 768+215 nm (Figure 2.2A and B). This formulation of 
POH-PLGA was used in subsequent studies. 
Usage of the free form drug does not allow attainment of effective concentration unless 
a large payload is administered, which ironically results in many untoward effects. In such 
cases, drug-delivery systems offer help by providing continuous and constant supplv of 
the therapeutics for an extended time period. The hydrophobic POH is likely tc be 
physically dispersed by its encapsulation throughout the matrix of PLGA particle. The 
release kinetics of the entrapped drug showed an overall slow and sustained release that 
was likely to be regulated by rate of polymer biodegradation. The release kinetics of 
entrapped drug was determined by incubating the dmg-bearing microparticles in PBS, 
pH 7.4 at 37°C to simulate physiological conditions. The amount of released POH was 
68 
Chapter 2: Anticancer efficacy of perillyl alcohol-bearing PLGAmicroparticles 
estimated by reverse phase HPLC analysis. A Hnear release of POH accounted for 
around 22% of the total POH entrapped in PLGA microparticles. In concurrence with 
earlier reports, where PLGA with the 50:50 ratio of lactic:glycolic acid composition was 
found to degrade in 1-2 months (Middleton & Tipton 2000), the in-house-prepared 
PLGA microparticles acquired steady release and showed 30% release of entrapped 
i 
molecules in a time span of 7 days (Figure 2.2C). 
Both in vitro and in vivo toxicity data revealed that POH bearing PLGA microparticles 
had negl%ible toxicity when compared with free form of the drug and thus assures its 
safety (Figure 2.3 and Table 2.1). The cytotoxicity of free POH was next examined, 
and it was found that POH had an IC50 of 25 [ig/mL against A253 human epidermoid 
cancer cells (Figure 2.4). This concentration was used to analyze differential cytotoxicity 
of free and PLGA microformulation-encapsulated POH and their comparative potential 
in induction of apoptosis in epidermoid cancer ceU Une. Due to faster uptake and 
subsequent release of the dmg by POH-PLGA microparticles, it exerts more cytotoxic 
effect on epidermoid cancer cells than its free form (Figure 2.5). This obsen^ation i ould 
be explained on the premise that application of POH-PLGA microparticles dclivefs a 
high amount of active drug at the tumor site mainlv. Further, polymer conjugation ol low 
molecular weight drugs alters their biodistribution; enabling their passive tai^eting and 
reducing access to sites of toxicity (Duncan 2006). Aiicroparticle-based drug 
formulations entertain a special status in improving the efficacy of drug against many-
types of cancers. Therefore, the present smdy was extended to gam insight in POH-
PLGA microparticle-mediated modulation of various proteins involved in the apoptosis 
of A253 cells. Western blot analysis was perfoimed to determine levels of various cell 
cycle and apoptosis regulating factors. As evident from Figure 2.6A, incubation of 
POH-microparticle formulation with epidermoid cancer cells resulted in enhanced 
expression of p21/wafl when compared with free form of POH The expression of 
another important pro-apoptotic factor Bax was also analyzed in A253 cells upon their 
I 
incubation with POH-microparticle formulations. The POH-microparticle formulation 
up-regulates the expression of Bax, thereby enhancing apoptosis induction in cancer cells 
(Figure 2.6A). In the control groups (cells treated with sham PLGA microparticles), the 
expression profile of these molecules was not significantly affected when compared with 
POH-PLGA microparticles, suggesting that microparticle-based formulation is effective 
in upregulating p21/wafl and Bax gene expression. The effect of POH-PLGA 
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microparticles on expression of pro-apoptotic molecules was more prominent after 24 
hours incubation (Figure 2.6B). Interestingly, the POH-PLGA microparticle was 
equally successful in downregulating p53-mutant expression in A253 cancer cells (data 
not shown). Of note, both p53 and/or p21-dependent and -mdependent pathways have 
been previously reported to be involved in POH-induced cell cycle arrest and apoptosis 
in cancer cells; however, the extent of the cell responses varied and can be attributed to 
the mechanism operative in a specific cell type involved and the doses of the drug used 
m the study (Clatk et al 2002, Ariazi et al. 1999). 
DMBA, a polycyclic aromatic hydrocarbon, is metabolized to chemically reactive 
electrophile and initiate a cascade of reaction that eventually results in carcinogenesis by 
covalent interaction(s) with DNA (Dipple et al. 1984). Further investigations suggest 
that it induces skin papilloma in animal models by mutagenesis in Ha-ras oncogene 
(Bizub et al. 1986).36 Upon topical application of POH-PLGA microparticles, 80.8+5.2 
regression in tumor size was observed after the treatment, whereas free form POH 
showed only 65.1+7.1 regression (Figure 2.7). Increased regression in the POH-PLGA 
microparticle group could be attributed to sustained release of P O H InterestingK", tne 
tumor regression results were found to have great correlation with sun/ival rate of the 
treated animals. In case of POH PLGA microparticles, survival rate was highest (80*^ /o) 
over a period of 13 weeks when compared with survival rate of the animals treated with 
free form POH (40%) (Figure 2.8). Further, histopathological analysis of the skin 
tissues isolated from treated animals was performed and the restilts clearly demonstrated 
that free form POH had more acanthosis and papillary growth than POH-bearing PLGA 
microformulations (Figure 2.9). The pro-apoptotic gene p53 regulates the balance 
between cell proliferation and cell death (Croce 2008, Knudson 2001). It has been 
observed that the p53 gene gets mutated in most types of the malignancies, including 
sarcomas. Upon exposure to a potent carcinogen, the toxic insult of the cell is generally 
nullified by a chain of cell cycle regulatory events programmed to check the uncontrolled 
proliferation by a suitable repair mechanism (Branzei & Foiani 2008). The failure to 
induce expression of functional p53wt leads to deregtilation of cell cycle arrest or cell 
death and tumor progression. The results of the present study showed decreased p53-
mutant expression upon treatment with POH-bearing PLGA microparticles. Also, higher 
efficacy of the microparticle-based formulation of POH can be correlated with 
upregtilated expression of p53wt and p21/wafl genes (Figure 2.10). 
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The survival data further establish higher supremacy of POH-PLGA microparticles over 
its free form. The observed higher efficacy of POH-bearing PLGA microparticle 
formulations can possibly be attributed to the greater bioavailability of POH and its 
accumulation at the tumor site. Finally, it can be inferred that microparticle-based 
formulations not only overcome the solubility constraints of the poorly water soluble 
i 
POH but also facilitate its release in regulated fashion that eventually results in better 
efficacy of POH in terms of tumor regression and survival of treated animals. 
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Chapter 3: Chemotherapeutic efficacy of curcumin bearing microcells 
Hepatocellular carcinoma (HCQ is a malignancy of worldwide significance and has 
become an increasingly important subject in the United States. Currently HCC is the fifth 
most common solid tumor across the globe and the fourth leading cause of cancer-
related death (Parkin et al 1999). Treatment modalities for the HCC have been well 
documented Qohnson 2000, Cuiiey 2000, Nakakura & Choti 2000). Despite 
i 
availability of innumerable options, diagnosis of HCC remains underecored at early stage. 
Most of the published research work shows that systemic chemotherapy response rates 
between 0-25%, and in spite of therapy it has never showed prolonged survival in treated 
individual (Simonetti et al. 1997). So there is a growing need for new anticancer agents 
that could provide an alternative to synthetic drugs. In a sui^e to discover novel 
chemotherapeutic agents natural products are providing templates. 
Recent studies on tumor inhibitory compounds of plant origin have resulted in an array 
of novel therapeutics. Different phytochemicals including dietar)^  agents and nutrients 
have been found effective against various types of cancer. Those active substances 
include vitamin derivatives, flavenoic and phenolic derivatives, sulphur comaining 
compounds and isothiocyanates. One such phytochemical, curcumin (difrulo}-! methane) 
found in lar^e quantities in the roots of Cummu longa (Shishodia et al. 2005), has been 
used as a spice and colouring agent in Indian and Chinese food for centuries, also it has 
been utilised as therapeutic agent (Figure 3.1). Curcumin possess antioxidant, anti-
inflammatory properties and inhibits chemically induced carcinogenesis in the skin, fore-
stomach, colon, and liver (Inano et al. 1999, Chuang et al. 2000, Singh et al. 1998, Li 
et al. 2002, Kawamori et al. 1999). 
HO" 
OCH, OCfl 
Figure 3.1 Chemical structure of curcumin 
Despite their high efficacy, phytochemicals possess high dose associated toxicity and 
other side effects. Moreover, their non-tai^eted accumulation, fast elimination and poor 
solubility complicate the issue. Novel chemotherapeutic agents identified through 
different combinational screening procedures have solubility problem (Merisko-
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Liversidge et al. 2003). Although curcumin does not possess any toxicity even at high 
dosage but its bioavailability is very poor. That is the reason why it has not been 
translated into clinical settings yet. There has been intensive research to overcomt; its 
bioavailability and solubility issue. With the aim to increase its bioavailability^ we 
encapsulated it in different types of microparticle based formulations. Choice of 
polymers to be used for the formation of microparticles should be made according to the 
application. In case of cancer therapeutics, it should have good entrapment efficienc\' 
and longer degradation period to ascertain sustained release. We opted for poly lactic 
glycolic acid (PLGA) and phosphatidyl choline (PQ to encapsulate curcumin. PLGA is 
non-enzymatically degradable polymer. Its degradabiUty depends on the molar ratio ot 
lactic :glycolic acid (Middleton & Tipton 2000). We used PLGA with molar ratio of 
lacticrglyrolic 50:50, as it has been used widely for drug delivery applications. We also 
entrapped curcumin bearing PLGA microparticles in PC liposomes (microcells) to 
resolve burst release issue. Thus formulating such compounds using different delnvn 
svstems could be a plausible solution. PLGA and PC have been used extensiveK' to 
formulate such compounds, also their formulation showed better efficac\" and enhani ed 
activity than the native molecule (Farazuddin et al. 2011). Both ot them have advaniai;c 
of being biodegradable and non-toxic (Vemia et al. 2011, Pietzyk & Henschke 2C03) 
and have been used u-idely in treatment of infectious diseases and cancer as well (Jain ct 
al. 2011, Riganti et al. 2011). 
In the present study, we report synthesis of curcumin bearing microcells and compare 
their efficacy with PLGA microparticles. We also studied their toxicity and curcumin 
biodistribution along wth its application in treatment of di ethyl nitrosamine (DEN) 
induced hepatocellular carcinoma. 
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Curcumin, egg PQ cholesterol, PLGA and polyvinyl alcohol (PVA) were procured from 
Sigma Aldrich Company (St. Louis, USA). Anti-p53 wild type, anti-bax, anti-bcl-2 and 
anti-p-actin antibodies were purchased from BD Biosciences (San Diego, CA). Liver and 
kidney function tests were performed using the kits, bought from Span diagnostics, 
India. Rest of the chemicals were of analytical grade and procured locally. 
Preparation of Curcumin bearing PLGAmicroparticles 
Microparticles used in the present study were prepared by oil-in-water (O/W) emulsion 
solvent evaporation technique using published protocol as standardized in our laboratory 
(Jeffery et al. 1993). Briefly curcumin (30 mg dissolved in minimum volume of DMSO) 
was mixed uith PLGA solution (190 mg PLGA dissolved in 0.5 mL di chloro methane) 
and sonicated in bath type sonicator to emulsify. The emulsion was added to 10% PVA 
solution (50 mL) and homogenized using a Silverson L4RT Homogenizer (Silverson 
JVlachines, East Longmeadow, MA) and the resulting suspension was stirred under 
ambient temperature (25°C) for 18 hours to allow solvent evaporation leading to 
curcumin loaded microparticle formation. The microparticles were centnfuged at 10,000 
.\ g for 10 minutes and v>-ashed with PBS (pH 7.4), to remove unentrapped dmg. The 
micropaiticle based formulation was lyophiHzed and finally stored at 4°C till fuither use. 
Preparation of PLGA microparticles bearing microcells 
Curcumin bearing microparticles were entrapped in PC liposomes by freeze and thaw 
method. Briefly PC liposomes were prepared from egg PC (49 ^mol) and cholesterol (21 
/Mmol) using published method v^ nith some modifications as standardized in our laborator}^ 
(Khan et al. 2004). Curcumin bearing PLGA microparticles were mixed with blank PC 
liposomes and several cycles of freeze and thaw were repeated for their encapsulation. 
The smallest fraction of PLGA microparticles was used for encapsulation in PC 
liposomes. This was achieved by centrifuging prepared PLGA microparticles at 2000 x g 
for 5 minutes and supernatant having small size microparticles were separated. After 
freeze and thaw cycles microcells bearing suspension was subjected to sonication for 5 
minutes in a water bath sonicator (Power Sonics 405, Seoul, Korea). This suspension was 
centnfuged further to 5000 x g for 5 minutes. After centrifugation supematant having 
blank liposomes was discarded and middle layer having only curctimin loaded 
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micropaiticles was separated from microcells. This fraction of microcells was further 
used for its characterization. 
Entrapment efficiency of curcumin in PLGA microparticles and microcells 
\\-as The entrapment efficiency of curcumin in PLGA microparticles and microcells, 
measured by dissolving 10 rr^ of freeze dried formulations in 1.0 mL of 0.1 N NaOH 
Qeffeiy et al. 1993). This solution was vortexed and then incubated at 37°C for 1 hour. 
After incubation solution was centrifuged at 9168 x g at 25°C for 10 minutes and 
supematant was examined for curcumin using HPLC Qayaprakasha et al. 2002). 
Briefly, an aliquot (100 [xL) of supematant was mixed with 900 ^L methanol. ITie 
suitable aliquots, of the resultant homogenate solution, were analyzed by reversed phase 
HPLC using a Symmetry® C18 column (3.9 mm x 150 mm). The solvent system used 
was isocratic acetonitrile:methanol:water (55:35:10 v/v). A standard cur\'e of the drug 
was plotted at 425 nm by determining the area under curve corresponding to the knowii 
(increasing) amount of the dmg. 
In vitro release kinetics of curcumin from PLGA micn^particles and micrc>cells 
For PLGA microparticles and microcells, mukiple samples of given tormulation were 
weighed and dispensed into various micro vials. To each vial, 1.0 mL of 20 mM sterile 
PB was added. The vials were placed at 37°C. 100 ^1 of PB was removed bv 
centrifugation at 9168 x g for 10 minutes and fresh buffer was exchanged at everv time 
point thereafter. The content of curcumin was determined as described previouslv 
(Jayaprakasha et al. 2002). Released curcumin concentration was calculated from the 
standard ctirve of the dmg plotted in presence of 20 mM PB. 
Animals 
For in ziw studies female Swiss albino mice (weight 20+2g) were obtained from 
institute's animal house facility and were kept on standard pellet diet (Hindustan lever 
ltd) and water ad libitum Animals were checked twice daily for mortality and morbidit\-
prior to the commencement of the smdy and only heakhy animals were used for in uzo 
experiments. The techniques used for mice handling, bleeding, injection and sacrifice 
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were strictly performed as per the guidelines of CPCSE A (committee for the purpose of 
control and supervision of experiments on animals), Govt. Of India. 
Toxicity tests for curcumin formulations 
A new formulation of any drug molecule has to be tested for any inherent toxicity before 
being used for efficacy studies. Toxicity issues were tested both in utro and in uw. 
Preliminary acute drug toxicity was tested through in utro erythrocyte lysis test wherein 
haemoglobin, released as a result of membrane leakage or disruption caused by exposure 
to therapeutic dosages of the dmg, is measured (Khan et al. 2002). Briefly, fresh blood 
was obtained from a healthy rabbit and collected in anticoagulant solution (EDTA), 
followed by centrifugation at 9168 x g for 10 minutes at 4°C. Buffycoat as well as plasma 
was discarded and erythrocytes were washed with PBS, pH 7.4 thnce. The washed 
erythrocytes were diluted with isotonic buffer (20mM PBS) and 50% haematocnt was 
prepared. To study extent of haemolysis, the suspension of RBG was incubated uith 1.0 
mL of free form as well as microcells and microparticles encapsulated curcumin (10 
mg/niL) at 37°C for 1 hour. Free fonn of curcumin was dissolved in 50 u^L of DMSO 
and finally volume was made up to 1.0 niL with PBS (final 5% D\'ISO). .\fter 1 hour the 
reaction mixture was centiifuged at 1500 x g and supernatant was collected and analwed 
by UV-Visible spectroscopy (/.max=576nm) for released haemoglobin. The percent 
haemoly'sis was determined by the following equation: 
[(AbT - AbsC)/Absl00% - AbsC)] X 100 
where AbsT is the absorbance of the supernatant from samples incubated with the dmgs, 
AbsC is the absorbance of the supernatant from controls (PBS) and Absl00% is the 
absorbance of the supernatant of controls incubated in the presence of 1% Triton X-100 
which causes complete lysis of RBG (total haemolysis). 
Hepatic and renal toxicities -w^ ere monitored by applying multidose regimen (total three 
doses, at altemate days) to determine biochemical profiles of semm creatinine and 
alkaline phosphatase (ALP). The blood was collected by retro-orbital puncture from the 
mice of different groups after last dosage. The blood was allowed to clot at room 
temperature and serum was separated for investigation of creatinine and ALP as per 
respective guide provided by the manufacturer. 
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In vivo bio-distribution studies of curcumin 
/n •azo biodistribution studies were carried out in Swiss albino mice weighing 20 ±2 g. 
Biodistnbution studies had following experimental animal groups,^ __each__having 10 
animals. 
Group I Free form or curcumin / ( ,_ 
Group II Curcumin encapsulated PLGA microparticlea 
Group III Curcumin bearing microcells X ^ .^^•v^-^.^wj-^^s^: 
Different curcumin loaded formulations as well free form of curcumin, were injected via 
intraperitoneal (£/?.) route at a dose of 200 mg/kg b.w. of animal. Only single injection 
was administered. At different time points blood was collected by retro orbital puncture 
and animals were sacrificed for the quantification of drug. Similarly, different organs 
(liver, kidney and spleen) were taken out asepticaily, washed 'w.ath RPMI medium. Organs 
were rinsed using tissue paper and weighed. Now organs were homogenized using HPLC 
buffer and centrifuged at 9168 x g. Supematant was collected for HPLC examination and 
the amount was calculated from the standard plotted with respective or^an. In case ot 
blood, It was centnfuged at 1000 x g tor 10 minutes and semm was collected. Seaim 
proteins were precipitated 'with the HPLC buffer and centrifuged at 9168 x g for 10 
minutes. Supematant was collected and examined for curcumin concentration. 
Induction of Liver cancer by di-ethyl nitrosamine 
Liver cancer in experimental models was induced as described elsewhere and as 
standardized in our laboratory (Pitot et al. 1978). Bnefly DEN at a dose of 2.4 mg per 
animal was injected intraperitonealy {ip) and monitored for 40 days. After incubation 
period treatment was started. 
Assessment of anticancer efficacy 
The efficacy of curcumin based formulations was assessed by examining various 
parameters including liver enzymes, percent survival, liver histology and Western blot 
profile of apoptotic molecules. Curcumin was used at a dose of 50 mg/kg body weight as 
this dose already has been shown to reduce tumor incidence and increased survival in 
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ascites mice model (Kuttan et al. 1985). All formulations of curcumin were given 
through ip. route for a period of 10 days after induction of tumor and then were left for 
resting period (30 days) to observe the effect of formulations. Animals were divided into 
following groups. Each experimental group had 10 animals. 
Group I Healthy control 
Group II Untreated control (DEN treated only) 
Group III Sham PLGA microparticles 
Group IV Sham microcells 
Group V Free curcumin (50 mg/kg) 
Group VI Curcumin loaded PLGA microparticles (50 mg/kg) 
Group VII Curcumin bearing microcells (50 mg/kg) 
Assessment of Liver enzymes 
It had been shown that liver enzATiies get up-regulated in cancerous conditions (Girr et 
al. 2010). Hence efficacy of curcumin based formulations was assessed b\- moniionug 
the level of different liver enz\Tnes ziz; alkaline phosphatase (ALP), aspait.te 
transaminase (AST) and gamma glutam}4 transferase (OCT) in treated animals. 
TNF-a expression 
TNF-a is a member of TNF superfamily and contributes in immunity, also takes part m 
apoptosis and cell survival (Aggarwal et al. 2006). TNF-a concentration was measured 
from serum samples of various treated groups using ELISA. ELISA was perfomied <is 
per the manufacturer's guidelines. Briefly, 50 ixL of the puiified capture antibody was 
coated on polystyrene microtitre plates at 4^0 in carbonate buffer pH 9.4 ovemight. 
After incubation plates were washed five times with PBST and blocked with 5% 
skimmed milk After 1 hour incubation at 37°C, plates were washed with PBST and 
incubated with 50 fiL sample for the detection of cytokine. After 2 hours of incubation at 
37°C plates were washed and coated with biotinylated anti-mouse TNF- a (detection 
antibody). Now plates were washed thrice with PBST and 100 fjL of streptavidin-HRP 
was added. It was incubated for 30 minutes at room temperature. Plates were again 
washed three times with PBST and finally developed with tetra methyl benzidine. The 
absorbance was read at 450 nm with microtitre plate reader. A standard was also plotted 
using (known concentration) of recombinant TNF-a. 
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Preparation of whole cell fraction 
The liver was removed from experimental mice and was placed on ice. The samples were 
homogenized in the presence of protease inhibitor cocktail, and the nuclear fraction was 
prepared according to the protocol published elsewhere (Serpi Ket al. 1999). 
Western Blotting 
The while cell fraction was analyzed for the presence of various apoptotic molecules 
using Westem blotting method (Towbin et al. 1979). Briefly, the protein content of the 
homogenate was estimated by the routine method using bovine serum albumin as a 
standard (Lowry et al. 1951). Proteins (30/Lig/well) were resolved under denatuiing 
conditions on 10% SDS-PAGE and electro blotted onto nitroceOulose membranes. Hie 
blots were blocked ovemight wth 5% non-fat dry milk and probed wth appropnate 
antibodies at the dilutions recommended by the suppliers. To quantify equal loading, 
membranes were reported -with a-tubulin antibody. Data are presented as the relaiive 
pixel densit}'of each band normalized to a band ot a-tubulin. The intensity of the b.mci 
was quantitated using image anaH-sis sotrware an Image gel documentation s\-stem. 
Statistical analysis 
All graphs were plotted using MS-Office excel 2007. Different analyses were done using 
SigmaPlot 11.0. The Kaplan-Meier anahsis was used to estimate survival and differences 
were analyzed by log-rank test. 
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Characterization of curcumin bearing PLGA microparticles and microcells 
Sizing of the prepared microcells were done using Nanophox size analyzer. In the 
previous chapter, we reported the size of PLGA microparticles to be 768 ±215 nm but 
after centrifuging the aliquot small size microparticles used for encapsulation in PC 
liposomes were found to be of the size 510 ±82 nm. In the present study, we observed 
that upon encapsulation of PLGA microparticles in PC liposomes their size was 
increased and, in-house prepared microcells had average size of 810±188 nm (Figure 
3.2A). Further, we performed release kinetics of curcumin from different formulations 
using PB (pH 7.4) at 37°C PLGA microparticles showed 17% release of curcumin in 2 
days which increased very slowly till 7''' day (28%) whereas in case of curcumin bearing 
microcells release was comparatively very slow. In 2 days, it released 4% content which 
increased upto 16% in 7 days time span (Figure 3.2B). Curcumin bearing PLGA 
microparticles showed burst release partem whereas microcells had very sustained release 
initially that increased gradually over extended time period (Figure 3.2B). 
Toxicity Test 
In vitro toxicity 
Newly developed various curcumin based fomiulations were evaluated for in utm toxicity 
by RBC lysis test. Figure 3.3 shov.'s the lysis caused by different curcumin based 
formulations. 100% lysis of RBC caused by Triton-X-100 was considered as total RBC 
lysis. Lytic ability of blank microparticles and microcells was also examined. In the 
Figure 3).2> it's shown that curcumin bearing PLGA microparticle and microcells caused 
negligible lysis as compared to free form of curcumin. 
In vivo toxicity 
In liw toxicity of different curcumin based formulations was examined by estimation of 
hepatic and renal parameters. Animals were treated with different curcumin dosages as 
described in eariier section and semm was isolated for the evaluation of creatinine and 
ALP. Untreated animals served as control for the comparison study. As showed in Table 
3.1 curcumin based formulations did not have elevated renal and liver function 
parameters. 
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Figufe 3.2 Characterization of curcumin beaiing mictoceUs. Size characterized 
using Nanophox size analyzer (A), release kinetics of curcumin frota mictocell and 
PLGA microparticles in 20mM PBS (pH 7.4) at 37°C using HPLC (B). Curcumin release 
kinetics was determined as described in materials and methods. Data represented here is 
mean of three different experiments ± SD. 
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I Control 
15% DMSO 
I Sham-PLGA-microparticles 
I Sham mkroceiis 
I Free curcumin (5% DMSO) 
I Curcumin-PLGA-microparticles 
I Curcumin-bearing microcells 
Figure 3.3 Eiythfocyte lysis test: la vitro toxicity was measured by etyduocyte 
lysis caused by different curcumin formulations. Haemolysis test was performed as 
described in materials and methods. Data represented here is mean of three different 
experiments + SD. 
Table 3.1 Concentrations of creatinine and ALP in plasma of animals treated with 
curcumin formulations. 
Groups Creatinine (mg %) ALP (lU/L) 
Contiol 0.27±0.052 
Sham PLGA mictoparticles 0.3010.28 
Sham microcells 0.24±0.034 
Free curcumin (50 mg/kg) 0.36±0.038 
Curcumin PLGA microparticles (50 mg/kg) 0.28±0.32 
Curcumin bearing microcells (50 mg/kg) 0.22±0.011 
3Z23±Z10 
38.4211.46 
33.8213.40 
42.3911.29 
35.1212.42 
36.6512.28 
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Bio-distribution of curcumin 
Numerous reports have been published about the curcumin formulation development 
and their m dim efficacy but they do lack data of its bio-distribution (Karikar et al. 2007, 
Li et al. 2005). We developed curcumin based PLGA microparticles and encapsulated 
them in PC Liposomes with the aim to increase its bioavailability and in turn to enhance 
its shelf life and in liw anti-cancer efficacy. 
As shown in Figure 3.4A, liver tissue had very high concentration of curcumin at 2 hour 
post injection which declined very fast in the free form treated group. After 24 hours, it 
was not detectable. In case of PLGA microparticles treated animals, initially lesser 
amount of curcumin was detected which increased upto 12 hours post injection, .\fter 
that its concentration reduced but it was still detectable 24 hours post injection. We 
observed increasing concentration of curcumin in microcells treated animals. Initially it 
had 29.65 ^g/g concentration which increased upto 78.8 Mg/g after 72 hours post 
injection. 
Further curcumin's bio-distnbution was examined in kidney's ot treated animah. AN 
shown in Figure 3.4B, free form treated group had 29.5 /xg/g curcumin at 2 houi^ post 
injection. Its concentration was decreased kitther and only 5.21 ^g/g curcumin was 
detected after 24 hours. PLGA micropanicles treated animals had 32.61 IJ%/% initiallv 
which was decreased further but the concentration was still detectable after 72 hours 
(0.38 /L<g/g). Microcells treated group showed increasing pattem of the curcumin and at 
starting point it had 7.08 /xg/g that increased upto 28.42 /ug/g at 48 hours. 
We also examined serum curcumin concentration in different curcumin formulation 
treated groups. In free curcumin treated group, curcumin level was very high at 2 hours 
post injection that came down very fast and could not be detected beyond 24 hours post 
treatment. Although PLGA microparticles and microcells did not have high 
concentrations of the compound initially, but it increased slowly and both groups had 
highest curcumin concentrations 13.27 and 19.99 /tg/g at 24 hours. Beyond this time 
point curcumin level declined in both the treated groups although it was still detectable. 
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Figure 3.4 Bio-distribution of curcumin from different formulations in various 
vital organs and blood of treated animals. (A) Liver, (B) Kidney and (C) blood. 
Curcumin distribution was analysed as described in materials and methods section for a 
period of 72 hoxirs. 
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Cufciunin loaded PLGA mictopatticles and mictocells mediated livet enzymes 
snpptession 
We measured the activity of some important livet enzymes in treated groups. Alkaline 
phosphatase activity decreased significandy upon treatment with curcumin bearmg 
microcells when compared with free cutcumin (microcells penus free curcumin; /KO.Ol). 
Curcumin PLGA microparticles also showed low level of ALP but it was not significant 
(curcumin PLGA microparticles tvrxus free curcumin;/)<0.07) (Figure 3.5A). 
Untraated animals 
Curcumin (free form) iso 
Curcumirt-bearlne mScroceBs -g-
Curcumin-PLSA microparticles 
140 
^ 1 2 0 
? 100 
(B) 
• Healthy animals 
• Umreated animals 
• Curcumin (Free form) 
• Curcumin-bearine microcelh 
• Curcumin-MGA-microparticles 
400 
go 
N 60 
40 
20 
• Healthy animals 
• Untreated animals 
• Curcumin (Free form) 
• Curcumin-bearing microceils 
• Curtumtn-PtGA-micreparticles 
300 
Figute 3 J Livet enzyme levels in animals treated with various cutciunin 
formulations. Liver functioning enzyme activities were measured as described in 
materials and methods. Data represented here is mean of three different experiments ± 
SD. (A) ALP (microcells perats free curcumin, p<0.01; curcumin PLGA microparticles 
versus free curcumin;/><0.07) (B) AST (microcells versus free curcumin, ;><0.05, curcumin 
PLGA-microparticle versus free curcumin;/)<0.05) (C) GGT. 
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Further activity of AST was measured in different experimental groups. As shown in 
Figure 3.5B its activity decreased in both curcumin bearing microcells and PLGA-
microparticle groups significantly when compared with free curcumin (microcells XErsts 
free curcumin; pO.05, curcumin PLGA-microparticle imus free curcumin;/?0.05). We 
also examined the level of GGT in different treated groups. Although curcumin bearing 
microcells and PLGA microparticles both sho-^ing decreased level of GGT in 
comparison to free curcumin but the difference was not significant (Figure 3.5C). 
Curcumin loaded PLGA microparticles and microcells downrcgulate TNF-a level 
Initially Tumor Necrosis Factor was discovered for its anti-tumor activity but now it has 
been shown to mediate initiation, promotion and tumor metastasis (Kunnumakkara et 
al. 2008). Curcumin modulates TNF-a induced signalling and acts as inhibitor of TNF 
expression (Aggarwal et al. 2006). In our study we measured TNF-a level in different 
formulation treated groups. Our results showed that both curcumin beaiing microcells 
and PLGA microparticles, dovvTiregulate the TNF-a expression. Although free tomi ot 
curcumin also dov-nregulated TNF-:< expression but it was not as significant as in 
microcells and microparticles treated groups (curcumin PLGA micropaiticles ux^iis 
curcumin tree from/7<D.05, microcells la^is curcumin free {xo\r\p<O.OS) (Figure 3.6). 
Increased survival of curcumin bearing PLGA microparticles and microcells 
treated animals 
We also monitored the survival in different formulation treated groups for a period of 12 
weeks. PLGA w h molar ratio 50:50, leads to sustained release of entrapped molecules 
as its degradation requires 1-2 months. Although PLGA microparticles also help in 
release for longer period but its release pattern was faster when compared to microcells. 
Sustained release pattem of entrapped curcumin increases its bioavailability, thus, 
enhances its efficacy. Our results demonstrated that curcumin bearing microcells showed 
most significant survival rate (80%) followed by curcumin-PLGA microparticles (70%) 
whereas free form of curcumin could maintain it only 20% survival (microcells wrsus 
curcumin free form;/;<i9.00i, curcumin-PLGA-microparticles imus curcumin free form; 
pO.OOl) (Figure 3.7). No animal survived in untreated, sham microcells and sham-
PLGA microparticles group beyond 9'*" week. 
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Figute 3.6 TNF-a expression profile of animals treated with different cutcumin 
formulations. TNF-a levels were measured in plasma as described in materials and 
methods. Data represented here is mean of three different experiments ± SD. 
(MicroceUs tvryus free curcxmiin; p<0.03, Curcumin PLGA micropartides tvryus free 
curcumin; p<0.05, Microcells versus Curcumin PLGA microparticles; p value not 
significant). 
-•-Curcumin-bearing microcells 
- * - Curcumin-PtGA-microparticle 
-*«-Curcumin (free form) 
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Figute 3.7 Siuvival gtaph of dififetent formulations treated experimental groups. 
Survival was monitored twice a day for a period of 12 weeks. Each group contained 10 
animals. Data represented here is mean of three different experiments ± SD. (Microcells 
versus free ctircumin; p<0.005, Curcumin PLGA tnicroparticles versus free curcutnin; 
/)<0.005, Microcells versus Curcumin PLGA microparticles;^ value not significant). 
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HistDpathological analysis 
As compared to healthy control, untreated group reveals impressive inductive effect of 
carcinogen on liver. Free compound group shows regression but is associated with 
poorly preserved hepatoceOular architecture. Curcumin bearing microparticles group has 
only mild effect but microcells encapsulated curcumin has moderate therapeutic effect. 
Sham PLGA-microparticles and sham microcells behaved as untreated group. Thus, if 
other factors are not taken into account then curcumin bearing microcells show marked 
recovery, followed by curcumin PLGA microparticles and then free form of the 
compound (Figure 3.8). 
Western blot analysis of apoptotic molecules 
In the last section of our experiment, we carried out western blot profiling of varitais 
apoptotic molecules to ensure the high rate of cell death in curcumin bearing formulation 
treated groups. As shown in the Figure 3.9 curcumin bearing microcells and P L ( J A 
microparticles had more inductive effect on liver whereas free form of curcumin had 
very low expression profile. Sham microcells and PLGA microparticles had the same 
expression as untreated group had (data not shown). Our data is suggestive of livei-
cancer regression in curcumin bearing microcells and PLGA microparticles treated 
animals by enhancing the expression of apoptotic molecules. 
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Figme 3.8 Histological analysis of different fotmulation ti^ated groups. Healthy 
controk shows noimal cords of hepatocytes and sinusoids (A). Untreated group: Shows 
hypercellularity, cellular and nuclear polymorphism and overtly hyperchromatic large nuclei 
with increase nuclear cytoplasmic ratio (B).Curciumn bearing microcells: Hepatic cords and 
sinusoids appear very similar to health control (C). Curcumin bearing PLGA 
microparticles: Shows increased cellularity, hyperchromatic nuclei, altered hepatocellular 
contour, distorted sinusoids (D). Free curcumin: Shows reduction in nuclear cytoplasmic 
ratio, poorly maintained hepatocellular contour and dilated sinusoids (E). Sham microcells 
and PLGA microparticles: shows poorly maintained architecture of hepatocytes with cancer 
growth very similar to untreated control (F & G). 
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Heatthy control Untreated Curcumin (free Curcumin-PLGA Curcumin 
control form) microparticies bearing 
microcells 
• p53wt HBax HBd-a 
Figure 3.9 Expression profile of apoptotic molecules from various formulation 
treated groups. Western blot assay of p53 WT, bax and bd-2 in liver extract from mice 
treated with various curcvimin formulations. 
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Latest advancements in the field of drug delivery have lead to the development of novel 
biocompatible and biodegradable drug delivery systems capable of targeting cells and 
tissues, specifically, without affecting adjacent cell types. They can be used for either 
active or passive targeting. In a quest to develop a nanocarrier for the delivery of 
hydrophobic curcumin, we have synthesized microcells and PLGA microparticles. CXir 
study ascertains that microcells and curcumin bearing PLGA microparticles besides being 
safe and free of any toxicity constrains, increase bioavailability and in turn their 
absorption in tissues. Further, we showed their potential as curcumin carrier in treatment 
of hepatocellular carcinoma in model animals. 
In the past decade, there have been numerous studies done to evaluate potency of 
curcumin against human cancer cell lines (Duvoix et al. 2005, Aggarwal et al. 2003, 
Agganval & Shishodia 2006, Choudhuri et al. 2005). Though curcumin showed ven-
strong activity against the cell lines examined but as a consequence of poor adsorption 
and fast elimination from body it could not show veiy promising results in tvw. In :he 
present stud}-, ^'t report synthesis of microcells, which were prepared b}" entrappuig 'he 
curcumin beanng microparticles in blank PC liposomes. We showed that P L ( J A 
microparticles size increased upon encapsulation in PC liposomes (Figure 3.2A). Owing 
to their comparative lesser stability, PLGA microparticles shov/ed faster release than 
microcells as they lack dual layer of PC liposomes (Figure 3.2 B). As shown by release 
kinetics performed at 37°Q both the delivery systems exhibit time dependent release 
pattern. Curcumin bearing microcells possessed much sustained release pattern than 
PLGA microparticles alone. Keeping into consideration that before application of any 
formulation, it is a pre-requisite to evaluate its toxicity in utro as well as in iiw, we 
performed various studies for any inherent toxicity issues. Curctimin bearing microcells 
and PLGA microparticles were found to be non-toxic as revealed by in utro RBC lysis 
test (Figure 3.3A). Further, it is also confirmed by in ziw LFT and RFT parameters, free 
curcumin as well as microcells and PLGA microparticles entrapped curcumin did not 
possess any toxicity at therapeutic dosage (Figure 3.3B). Before translating curcumin 
based formulation of microcells and PLGA microparticles inzizo, we also examined bio-
distribution of curcumin from various formularions. As shown in resuks, in free 
curcumin treated group, curcumin could not be detected in either liver or kidney beyond 
24 hours post treatment, although a very low serum concentration was seen in semm in 
microcells and PLGA microparticles treated groups (Figure 3.4C). In PLCrA 
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microparticles treated group curcumin concentration was relatively higher in all the 
organs examined. Initially its concentration increased but declined after a particular point. 
Curcumin bearing microcells maintained release pattern in a ver}^ much sustained manner 
that showed increasing curcumin distribution upto 48 hours (Figure 3.4A & B). In 
serum, it exhibited a similar release pattern as PLGA microparticles. 
In the subsequent phase of our studies, we induced hepatocellular carcinoma using Dt^N 
in model animals. We evaluated liver enzymes (ALP, AST and GGT) and TNI^ '-w 
expression in treated animals to ascertain the efficacy of our formulations in treating the 
induced cancer. Curcumin entrapped PLGA microparticles and microcells were found to 
significantly reduce liver enzymes in comparison to free curcumin (Figure 3.5). Most 
significant reduction was observed in curcumin bearing microcells treated animals which 
could be anributed to sustained release pattern of curcumin followed by PLCrA 
microparticles. Sham microcells and PLGA microparticles had no effect on li\er 
enzymes and they behaved as untreated group (data not sho-^ ^Ti). Qircumin also inhibited 
the activation of NF-xB that in turn reduces the expression of inflammaton- c\tokines 
and TNF-2. TNF-J : pla\'S an important role in tumor cell sun^ival and its differentiatiiMi 
and metastasis. Our results demonstrated that curcumin encapsulated microcells 
significantly inhibit the TNF-a expression followed by PLGA micropanicles whereas 
free form of curcumin had very mild effect (Figure 3.6). Sham microceUs and PLGA 
microparticles exhibit no effect on TNF-a expression (data not shown). 
Survival studies perfonned for a period of 12 weeks, showed a significant reduction in 
the moitahty of the animals. We anal}'sed that animals treated \\-ith curcumin beaniig 
microcells had maximum percent survival (80%) followed by PLGA microparticles grotip 
(70%) whereas free form of curcumin showed only 20% survival in the treated animals 
(Figure 3.7). Animals treated with sham microcells and PLGA microparticles did not 
survive beyond 9'^  week. Further tissue histology data revealed that curcumin beamig 
microcells were most effective in maintaining the cellular architecture (Figure 3.8). 
Though PLGA microparticles also showed better effect than free curcumin but it w.is 
not comparable to microcells treated group. Sham microcells and PLGA micropanicles 
behaved as untreated group (data not shown). 
Mutation in p53 tumor suppressor gene is a significant alteration in apoptosis pathway. 
Cells with mutated p53 gene result in functional inactivation of p53 and loose the 
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genomic integrity and escapes from apoptosis (Soussi 2000). Bcl-2 family of proteins 
impart in the apoptosis and share a balance in the cell. Bax, which is a dominant inhibitor 
of Bcl-2, induces apoptosis by its over-expression and mitochondrial damage. Further, it 
releases apoptosis mediators and cytochrome C and ultimately leads to cell death (Cory 
et al. 2003). With the aim to examine apoptosis, we evaluated expression of p53 WT and 
bax in the liver tissue extract of various curcumin treated groups. Western blot analysis 
of apoptotic molecules, p53WT and bax, also revealed that curcumin encapsulated 
microcells induced the expression of p53WT maximally followed by PLGA 
microparticles. Free form of curcumin was found to have very mild effect on expression 
of apoptotic molecules. Bax expression was upregulated in both curcumin entrapped 
PLGA microparticles as well as microcells treated groups (Figure 3.9). Sham PLGA 
microcells and PLGA microparticles had no effect on expression of either p53WT or bax 
expression (data not shown). 
Our results demonstrate that curcumin's bioavailability' increases upon encapsulation into 
PLGA microparticles and microcells. High dmg payload in liver improves the therapeutic 
index of curcumin thus helping in reduction of HCC Also, it can be concluded that 
microcells are sought to be more effective than PLGA microparticles. The difference in 
the chemotherapeutic effect owe to their release kinetics. 
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Cancer remains the major cause of death in most of the advanced countries and its 
incidence increases with aging. Cancer is catised by genetic instability and multiple 
molecular alterations (Hanahan & Weinberg 2000, Hahn & Weinberg 2002). As 
most of the diagnosis and treatment modalities available are inefficient, it is very difficult 
to treat cancer. 
r 
Chemotherapeutic drugs that are available for the treatment do not differentiate between 
cancerous and healthy cells robustly, hence, their unsystematic distribution leads to 
severe toxicity and hampers anti-cancer efficacy. Due to internal genetic diversiu- and 
having the ability to mutate rapidly, tumors turn to multi drug resistance, this is a more 
complicated issue to tackle. Also faster clearance of therapeutics from host body does 
not allow attainment of desired concentration thus reducing potential of therap^•. To 
overcome those drawbacks, efforts are being made to develop a suitable drug delnerv-
vehicle for instance liposomes, micelles, nanoparticle, and polymer drug conjugates 
(Blanco et al. 2011). However these technologies also have certain shortcomings such as 
in uwdms, leakage, premature degradation ot dehveiy vehicle and capacit\"to encapsuLue 
\-anet\' of therapeutics, which make them ineffective for packaging iherapcutKS 
(Vingerfioeds et al. 1996). 
Recentlv discovered RNA interference technolog}' has expanded greatly and emerged is 
powerful tool to treat cancer (Fire et al. 1998). The chief advantage of RNAi technology 
IS to target specific disease causing sequences and knock down their expression. /\s 
RNAi technology can be used to abolish function of any specific gene it can also be 
applied to tai^et the genes which play crucial role in cell survival. Cell sun'ival pla\^ a 
major role in cancer cells as they do have potential to bypass apoptosis and possess self 
sufficiency in growth factors to promote cell division and differentiation. There aie 
various genes reported that can be targeted to block cell survival (Kim et al. 2007, Xerri 
et al. 1998, Lacasse et al. 2005, Peltenbui^ et al. 2000, C N e i l et al. 2004). 
I 
COX-2 has effect on many processes that are important in cancer development, such as 
angiogenesis, apoptosis, inflammation, immunosuppression and invasiveness 
(Dannenbet^ et al 2001). Overexpression of COX-2 induces vascular growth factor 
production thus angiogenesis enhancement and apoptosis inhibition by alteration in 
apoptosis signaling molecules. It had been shown to be upregulated in a variety of human 
cancers including colon, gastric, esophagus, pancreas and breast cancer, while 
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vindetectable in most normal tissues (Eberhart et al. 1994, Subbaramaiah et al. 
1996, Ristimaki et al. 1997, Hida et al. 1998, Tuckered al. 1999, Zimmennan et al. 
1999). Furthermore, overexpression of COX-2 was sufficient to catise tumorigenesis in 
animal models and to render cells resistant to apoptotic stimuli (McGintyef al. 
2000, Lin ^r al. 2001, Cao & Prsscott 2002). Its role in cell survival also has been 
established (Oshima et al. 1996, Sawaoka et al. 1998). Taking these factors into 
consideration, we chose COX-2 for the treatment of hepatocellular carcinoma in model 
animals. 
In spite of gene silencing using siRNA, a wonderful technology, there are few challenges 
to be met yet. Innate immune system stimulation (Marques & "Williams 2005), non 
specific ui^eting (Kleinman et al. 2008), its rapid renal clearance and enzymatic 
degradation Qohn et al. 2007) are the main hurdles to be overcome. The last, but the 
most important, challenge in siRNA based therapy is the issue of delivery. RNA being 
anionic and hydrophobic in nature does not enter ceOs by difftision. Moreover, it's inuw 
deliverv at disease site is a major problem because naked siRNA is more prone to 
enz^Tnatic degradation in plasma. Other associated problems like limited penetration 
across the capillarv endothelium and inefficient uptake by tissues further complicate the 
issue. To overcome these difficulties, it is desirable to develop a suitable and effective 
delivery- s)'Stem. Although for siRNA delivery into the cytoplasm of cells, many vectors 
have been developed which are capable of delivering the contents in litro but there is still 
need of a delivery vehicle that could deliver siRNA in liw. Currently, siRNAs in clinical 
trials are directly administered to local tai^et sites thus avoiding the complexity of 
systemic delivery-. However, it is essential to introduce siRNA by a systemic route to treat 
most cancers and other diseases. A desirable delivery system should be biocompatible, 
biodegradable, and non-immunogenic. Second, the systems should provide optimum 
delivery of siRNA into target cells or tissues with protection of the active double-
stranded siRNA products from attack by semm nucleases. The siRNA delivery should be 
tissue targeted after its systemic administration, avoiding rapid hepatic or renal clearance. 
Finally, after delivery into target cells via endocytosis, the system should promote the 
endosomal release of siRNA into the cytoplasm, allowing the interaction of siRNA with 
the endogenous RISC. 
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In a quest to fulfil these requirements, we developed a delivery^  vehicle from BaaJlus 
sukilis (B.subalis) lipid which mimics as nanocell, and phosphatidyl choline (PQ based 
liposomes for the delivery of COX-2. B.suhilis lipid nanoceUs (Subtilosomes) and PC 
liposomes are biocompatible, biodegradable and do not induce any immune response. 
Also they have been used widely for drug and vaccine delivery application against 
infectious diseases and cancers as well (Deeba et al. 2005, Maroof et al. 2010, Khan et 
al. 2007). In the present study, we examined the efficacy of subtilosomes and liposomes 
for the delivery of COX-2 siRNA in treatment of di ethyl nitrosamine (DEN) induced 
hepatocellular carcinoma (HCQ in model animals. 
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All reagents used in the study were of highest purity available. siRNA, v/as purchased 
from Santa Quz Company (USA). Anti-p53 wild type (wt), anti-bax, anti-Cox-2 and anti-
p-actin antibodies were purchased from BD Biosciences (San Diego, CA). Liver enzymes 
were estimated using the kits from Span diagnostics (India). All others reagents were of 
analytical grade and procured from local suppliers. 
B. suhtilis lipids isolation, nanocell preparation and siRNA encapsulation 
B. subtUis was cultured in nutrient broth (1% peptone, 0.3% beef extract, 0.3% yeast 
extract and 1% sodium chloride; pH 7.4). The cells were harvested from mid-log phase 
(18-20 hours). Phospholipids were isolated by the method of Bligh Dyer, as modified by 
Kumar and Gupta (Kumar & Gupta 1983). The nanocells were prepared as described 
elsewhere (Ahmad et al. 2001). siENA was encapsulated using freeze and thaw method. 
Encapsulation of siKNA in PC liposomes by dehydration-rehydartion method 
siRNA encapsulated PC liposomes were prepared from egg PC (49 ixmol) and 
cholesterol (21 /xmol) using published method with some modifications as standardized 
in our laboratory (Khan et al. 2004). Briefly, lipids (20 mg) were dissolved in a minimum 
volume of chloroform:methanol (1:1 v/v). The solvents were evaporated carefully under 
reduced pressure to form a thin lipid film on the wall of a round bottom flask. Finally, 
traces of organic solvents were removed by subjecting the flask to high vacuum 
ovemight at 4°G Subsequently, the dried lipid film was hydrated with 2.0 mL of 150 mM 
sterile normal saline with intermittent vigorous agitation followed by sonication (30 
minutes, 4°Q in a bath type sonicator under nitrogen atmosphere. The sonicated 
preparation was dialyzed against normal saline for 24 hours at 4°C in the dari^ and then 
centrifuged at 10,000 X g for 30 minutes at 4°C to remove un-dispersed lipid. Now, PB 
containing siElNA was mixed with PC liposomes. The mixture was frozen and thawed 
several times and finally lyophilized to get free flowing dry powder. The powder was 
reconstituted with distilled water (1/10''' volume of the original solution). Thus prepared 
liposomal formulation of siRNA was used for further studies. 
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Entrapment efficiency of siRNA in liposomes 
Entrapment of siRNA in nanoparticles was assessed by the protocol published elsewhere 
and as standardized in our laboratory. Briefly, an aliquot of prepared liposomes was 
dissolved in 0.1% Triton X-100 followed by analysis of siElNA content by taking 
absorbance with UV spectrophotometer (Shimadzu). The percent entrapment efficiency 
(% EE) was calculated with the following formula. 
% EE = (Amount of siRNA entrapped)/(Total amount of siRNA used in the beginning) 
XlOO 
Animals 
Female Swiss albino mice of weight 20+2 were obtained from the institute's animal 
house facility. The animals were housed in poly propylene cages on wood powder 
bedding in an air conditioned ambience. Animals were quarantined on equal light/dark 
cycles (12/12 hour) and were kept on a pellet diet (Ashiiwad, Qiandigarh, India) and 
water cui lihtum Animals were examined for theu' mortality and morbidity poor to 
commencement of the study and only healthy animals were included in the experiments. 
The techniques used for administration of vanous formulations to animals were strictly 
performed following mandates approved by the animal ethics committee (Committee for 
the Purpose of Control and Supervision of Experiments on animals, Government of 
India). 
Induction of Liver cancer by di-ethyl nitrosamine (DEN) 
Liver cancer in experimental models was induced as described elsewhere and as 
standardized in our laboratory (Pitot et al. 1978). Briefly, single dose of DEN (120 
mg/kg b.w.) was injected by intraperitoneal route. After incubation of 40 days, animals 
were given the treatment. Liver cancer induction was ascertained by liver enzyme 
estimation and tissue histology. 
Assessment of anticancer efficacy 
Efficacy of SLRNA based liposomal formulations was assessed by examining various 
parameters including liver enzymes, percent survival, liver histology and western blot 
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profile of apoptotic molecules and Cox-2. siRNA was used at a dose of lOOnW 100/^ 1 
per animal. All formulations of siRNA were given through iv route (intravenous) for a 
period of 10 days after induction of tumor and then were left for resting period (15 days) 
to observe the effect of formulations. For our studies, animals were divided mto 
following 7 groups and each experimental group had 10 animals. 
Group I 
Group II 
Group III 
Group IV 
Group V 
Group VI 
Group VII 
Healthy control 
Untreated control (DEN treated only) 
Sham liposomes 
Sham nanocells 
SLRNA (free form) 
liposome siElNA 
nanocell siRNA 
Assessment of Liver enzymes 
It had been sho^ RTi that liver enz\Tnes get up-regulated in cancerous conditions (Carr et 
al. 2010). Hence efficacy of curcumin based nanopanicle formulations was assessed by 
monitoring the level of different liver enzvmes viz; aspartate transaminase (AST) and 
alanine transaminase (ALT) in treated animals. 
Preparation of whole cell fraction 
The liver was removed from experimental mice and was placed on ice. Sample was 
homogenized and the cell fraction was prepared using RIPA buffer. 
Western Blotting 
The nuclear fraction was analyzed for the presence of various apoptotic molecules using 
the Westem blotting method (Towbin et al. 1979). Briefly, the protein content of the 
homogenate was estimated by the routine method using bovine serum albumin as a 
standard (Lowiy et al. 1951). Proteins (30/^/well) were resolved under denaturing 
conditions on 10% SDS-PAGE and electro blotted onto nitrocellulose membranes. The 
blots were blocked overnight with 5% non-fat dry milk and probed with appropriate 
antibodies at the dilutions recommended by the suppliers. To quantify equal loading, 
membranes were reported with a-tubulin antibody. Data are presented as the relative 
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pixel density of each band normalized to a band of a-tubulin. The intensity of the band 
was quantitated using image analysis software an Image Gel Documentation System. 
Apoptosis detection with APO-BRDU labeling 
Liver cells were isolated using the protocol described and modified in our laboratory 
(Klaunig et al. 1981). Apoptosis detection from various formulation treated groups was 
performed tising Brdu staining kit (APO-BRDU kit, BD biosciences). Briefly, 1 X 10^  
cells/mL were suspended using 1% paraformaldehyde (dissolved in PBS pH 7.4). 
Suspended cells were placed on ice for 30-60 minutes. After fixation, cells were 
centrifuged at 500 x g for 5 minutes and supernatant was discarded. Cells were washed 
with PBS thrice and resuspended in 70% (v/v) ice cold ethanol. Cells were incubated on 
ice for 30 minutes. Cells were centrifuged at 300 x g for 5 minutes and ethanol was 
aspirated. Now cells were washed using wash buffer thrice and cell pellet was incubated 
with 50 ^1 DNA labeling solution at 37°C for 60 minutes. At the end of incubation 
period, 1.0 mL of rinse buffer was added and tubes were centiifuged at 300 x g for 5 
minutes. This was repeated three times and finally cell pellet was incubated with 0.1 mL 
of FITC labeled anti-Brdu antibody in the dark for 30 mmutes at room temperature. 
Now cells were analyzed PI/RNase staining buffer by How cvtometiy. 
Histological study 
To examine effect of siRNA entrapped nanoparticles on the development of tumor, 
three mice from each group were sacrificed by cervical dislocation and fixed in 10% 
formaldehyde solution. Tumor tissues were then excised and sections were prepared by 
using conventional paraffin sections and hemotoxylin-eosin staining. 
Statistical analysis 
One way ANOVA was used for comparing the mean values of tumor volume between 
various groups after ascertaining the homogeneity of variance between treatments. Post 
hoc analysis for comparing the two groups was done using the Least Statistical 
Difference (LSD) technique. The Kaplan-Meier analysis was used to estimate survival of 
mmor free animals and differences were analyzed by log-rank test. 
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COX-2 encapsulated liposomes mediatEd liver enzymes depletion 
It has been shown that entrapment of siRNA m a nanocanier not only circumvents its 
hydrophobicity but also delivers the contents in the cytosol of the cell and renders 
protection from premature degradation (Kim et al 2008). Nanocells constmcted with B. 
sukilis total lipid had entrapment 27 ±4.2% and in* case of PC liposomes it was 23±2only. 
In our studies we examined COX-2 siRNA delivery for the treatment of H C C COX-2 
has been shown to mediate the process of cancer proliferation. As a parameter, we 
examined activity of ALT and AST in the semm of animals treated with various siRNA 
based formulations. Our data showed that nanocells mediated delivery of COX-2 inhibits 
cell survival significantly and in turn downregulates the enzymes activity. Liposomes also 
helped in cancer regression but its activity was not comparable to nanocells. Naked 
siRNA had very little effect on the enzyme reduction (Figure 4.1). 
COX-2 mediated apoptosis induction in various siRNA treated groups 
In another set of experiment, to evaluate COX-2 mediated apoptosis, we isolated the 
liver cells and stained for Brdu and obseived with flow cuometry. Our results established 
that nanocells were most effective in delivering their content at tai^eted site and had 
maximum rate of apoptosis (18.53%) followed by liposomes (10.48%). Naked siRNA 
had only mild effect on apoptosis induction and it was only 7.53% Figure 4.2(1) and 
(II). Sham nanocells and liposomes had no effect on apoptosis. So, our results further 
demonstrated the superiority of nanocells over liposomes in delivering COX-2 SLRNA. 
Western blotting of apoptotic factors 
We also performed Western blotting of COX-2 and apoptotic molecules (p53 wt and 
Bax). As shown in figure 4.3, nanocells showed very little expression of COX-2 followed 
by liposomes whereas naked SLRNA had expression similar to sham nanocells, sham 
liposomes and untreated control groups. So our data clearly indicates the safe delivery of 
COX-2. COX-2 mediated ceU arrest was further confirmed by expression pattern of p53 
wt and Bax. p53 wt expression was induced in nanocells COX-2 siRNA significantly. 
Although liposomal siRNA group also had slightly high expression of p53 wt but not 
comparable to nanocells entrapped siRNA (Figure 4.3). Naked siRNA behaved as 
vehicle controls and had similar expression profile (Figure 4.3). 
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Figure 4.1 Livet enzymes levels in animals tteated with different siRNA bearing 
formulations. Enzyme activities were measured as described in materials and methods. 
Data represented here is mean of three different experiments ± SD. (I) ALT (Nanocells 
siRNA versus free siRNA; p<0.05, liposomes siRNA versus free siRNA; p value not 
significant, nanocells siRNA versus PC liposomes siRNA; p<0.09), (II) AST (nanocells 
siRNA versus free siRNA;/><(?.00.5, liposomes siRNA versus free siRNA;/)<0.05, nanocells 
siRNA mxwj-liposomes siRNA;^<0.005). 
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Figure 4.2 Apoptosis in liver cells analyzed by Brdu staining. Staining was 
performed using Brdu staining kit (BD biosciences) as described in materials and 
methods section. Figure 4.2(1) shows stained cell population from varioxis formulation 
treated groups. 
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Figute 4.2(11) depicts total percent cell population observed in different 
formulation treated gronps. 
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Figure 4.3 Expression profile of COX-2 and various apoptotic molecules fit>m 
various formulation treated groups. Western blot assay of COX-2, p53 wt and Bax in 
liver extract from tnice treated with various COX-2 siRNA bearing formulations. 
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Histology of liver tissue treated with siRNA based formulations 
Fuither histology of the liver tissue samples from various treated groups ascertained that 
nanocells were capable of delivering the COX-2 siRNA in liver tissues. Though free 
form of siRNA also had little effect on regression but not as significant as in case of 
nanocells and liposome based formulations (Figure 4.4). Sham nanocells and sham 
liposomes behaved as untreated control and showed very poor cellular architecture of 
liver tissue in treated animals (data not shown). Nanocells SLRNA and liposomes siRNA 
appear to have definite therapeutic role in prevention/treatment of induced liver cancer. 
Survival study 
HCCbearing animals treated with various formulations were monitored for their survi\al 
for a period of 12 weeks. In accordance of previous results nanocells entrapped COX-2 
siRNA had maximum survival rate (80%) followed by liposomes encapsulated sLRNA 
(50%). Naked siRNA as more prone to enzymatic degradation; had 20% sun^ival rate 
only (Figure 4.5). Sham nanocells and liposomes treated animals did not sur\'ive bevond 
9'^  week post treatment. Our results established that siRNA encapsulation of COX-2 not 
only provide it serum stability but also delivers the content at tai^eted site and helps in 
tumor regression, in tum increasing the survival rate of treated animals. 
106 
Chapter 4: siRNA bearing oanocells in tteatmcnt of hepatocellular carcinoma 
Figure 4.4 Photomictogiaphs of mice livet treated with various siRNA based 
formulatiotis. (A) healthy control shows notmal hepatocytes, sinusc»ds, and hepatic 
cords, (B) untreated control shows hypercellukrity, cellukr and nuclear polymorphism 
and overtly hyperchtomatic large nuclei with increase in the nuclear cytoplstnic ratio; 
distortion of hepatic cords and compression of sinusoids, free siRNA (C) shows only 
mild suppression but still many hepatocytes very akin to untreated control are visible. 
Liposomes siRNA (D) appears very akin to healthy tissues. Hepatocytes, their nuclei, 
cytoplasm, hepatic cords, and sinusoids appear normal in nanocell siRNA (E) treated 
group. 
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Figure 4.5 Suivival gtaph of di£Eerent COX-2 siRNA encapsulated fonnulations 
treated experimental groups. Survival was monitored twice a day for a period of 12 
weeks. Each group had 10 animals. Data represented here is mean of three different 
experiments ± SD. (Nanocells siRNA versus free siRNA; p<0.005, liposomes siRNA 
versus free siRNA; p<O.OS, nanoceUs siRNA versus liposomes siRNA; p value not 
significant). 
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Being specific and potent in activity, RNA interference is emerging as new generation 
wonder therapeutic. As siRNA inhibits at translation stage not at transcription, they do 
not interact with chromosomal D N A This phenomenon reduces the risk that is posed 
by DNA based gene therapy. Traditional drugs or chemically synthesized drugs only 
targets specific cell receptors, enzymes, ion channels or ligands. In biological molecule 
based therapy, only a part of cell surface receptors, tissue or blood component are 
targeted while siRNA based therapy has advantage of targeting mRNA of interest 
regardless of protem location. Another ug to add to this technology is that only few 
siRNA molecules are enoi^h to halt expression of particular gene (de Fougerolles et al. 
2007). But in spite of having these advantages siRNA could not be translated in clijiical 
settings successfully and possess certain issues to be surmounted. Most of the siRNA 
which are undergoing clinical trials are injected at the diseased tissue or in close 
proximity. Among various issues, major is to deliver them specifically and another is to 
provide them stability. Many techniques have been developed like chemical modification, 
lipid and polymer mediated delivery and polymer conjugates. In one such approach, we 
developed nanocell from B. suhtilis lipid and PC liposomes to encapsulate COX-2 tor the 
treatment of DEN induced liver carcinogenesis. 
Minicells from bacterial origin were first observed and reported by Adler et al m 1967 
(Adler et al. 1967) and later it was shown that minicells derived from bacterial ongin 
have capacity to encapsulate variety of chemotherapeutics (MacDiarmid et al. 2006). 
Since minicells are of bacterial origin, it is very much possible that they might induce 
immune response as bacterial products are known to activate potent inflammatory 
responses activated by Toll-like receptors (Shizuo & Takeda 2004). To avoid inclusion 
of lipopolysaccharides, we isolated lipid components only and further used them for the 
synthesis of nanocells. 
COX-2 is an important enzyme of prostaglandin synthesis and gets upregulated in 
various cancer types. This enzyme imparts in carcinogenesis and angiogenesis. Certain 
inhibitors have been developed to treat COX-2 mediated carcinogenesis (Kawamori et 
al. 1998, Oshima et al. 2001, Rioux et al. 1998, Shiotani et al. 1998, Stoiina et al. 
2001). But siRNA technology more sp)ecificifically provides better alternative to target 
COX-2. Liposome based delivery of various siRNAs has been reported to be safe and 
provides serum stability (Feigner et al. 1989, Kim et al. 2006), In the present study we 
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encapsulated COX-2 siRNA in B. stMlis lipid nanocells and PC liposomes, and their 
efficacy \i^s evaluated against liver carcinogenesis. We measured liver enzymes activity as 
a parameter to check the liver carcinogenesis and found that nanocells deliver COX-2 
much efficiently and helped in liver enzyme (ALT and AST) regression in treated animals 
(Figure 4.1). Being more stable nanocells showed more enzyme reduction than PC 
liposomes. siRNA in free form is more prone to degradation by serum endonucleases 
and hence possess very negligible activity. We also estimated apoptosis rate in isolated 
liver cells of various treated groups. Our results (Figure 4.2 I) showed that mnocelis 
were most successful in bringing about apoptosis in liver cancer cells followed by 
liposomes. The probable explanation for varying activity is their stability and capacity to 
deliver their content at targeted site. Again naked siKNA delivery did not have much 
effect on apoptosis induction. Sham liposomes had no effect on apoptosis induction. 
Percent apoptosis rate was 18.53, 10.43 and 7.52 in nanocells encapsulated COX-2 
siRNA, PC liposomes siRNA and free form of siRNA treated groups respectively 
(Figure 4.2 II). 
Apart from percent apoptosis measurement, we also elucidated the signalling pathway for 
cell cycle arrest. Apoptosis and cell cycle regulation are two interlinked processes. 
Abnormal cell differentiation leads to malignancy development and other abnormalities. 
Cell differentiation and apoptosis is maintained at molecular level. Every healthy cell 
maintains equilibrium of those molecules for cell differentiation, survival and apoptosis. 
p53, being a tumor suppressor gene induces apoptosis in response to DNA damage and 
saves cell from undergoing carcinogenesis. Bax is another molecule of its downstream 
signalling and is p53 target for apoptosis induction. So with the aim to analyze this p53 
mediated machinery of apoptosis, we performed Western blotting of p53 wt and Bax. 
We observed that p53 wt expression was maximimi in nanocells siRNA treated animals 
followed by liposomes siRNA Naked siRNA delivery had very mild effect on its 
upregulation (Figure 4.3). Same expression pattem was observed for Bax too. From 
those resuks we can interpret that liposome mediated COX-2 delivery successfully 
bduces apoptosis in liver cancer cells. Further, to validate these results we performed 
histology of liver tissues of various treated groups and monitored their survival. 
Histological staining also showed that nanocells mediated COX-2 delivery helped in 
cellular architecture maintenance. Though liposomes siRNA treated animals also showed 
better resuks but not comparable to nanocell siRNA Free form of siRNA had very wage 
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effect on carcinogenesis. Sham subtilosomes and liposomes treated animals behaved as 
untreated control (Figure 4.4). In accordance to our previous findings, we observed that 
nanocells COX-2 siRNA treated animals had 80% survival rate whereas liposomes 
entrapped siRNA and free siRNA had only 50 and 20% survival rate (Figure 4.5). 
On the basis of present findings, we can conclude that nanocells being more stable in 
nature deliver COX-2 SLRNA much efficiently than liposomes, helping in cancer 
regression and increasing survival in treated animals by bringing about apoptosis. We can 
conclude that B. subtilis nanocells mediated siE^A delivery provides serum stability and 
delivers large numbers of siRNA molecules and thus bears superiority over free delivery^  
of siRNA 
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Abstract: In the present study, a novel po!y-kictic glyeolic acid (PLGA)-based microparticlc 
formulation ofpenllyl alcohol (POIl) was prepared and characterized. Further. it.s efficacy wa.s 
e\aUiated against di-niethyl bcnzo anlhraccne-induccd skni papilloma in Swiss albino mice. 
The characterization studies showed thai I'OH-bcaring PLGA microparticles were of the size 
768 ±215 nm with a i^-potential value of-7,56 ± 0,88 mV. The entrapment efficiency of the 
active drug in panicles was 42.4% ± 3,5';.., l>OH-bearing PLGA microparticles were stable 
and released cnlrappcd Umg gradually over an extended time period. The in vitro efficacy of 
POH-bearing PLGA microparticles was e\aluated by examining their differential cytotoxicity 
and assessing their ability to inhibit epidermoid carcinoma cell line (A253), The POH-based 
microparticles when administered to tumcii-hcaring animals caused greater tumor regression 
and increased survival rate (-80%) as comn,iicd with ihc group receiving free form of POH 
(sur\ ival rate 40%), The superioi^ ity of P( )H-I'!.G.'\ microparticles over free form of POH was 
further evident from their ability to modui.;;c apoptosis-regulaiing factors. 
Keywords: poly-lactic glyeolic acid, epidermoid cancer cells, skin papilloma, aniicancer 
efficacy 
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Introduction 
Cytoto.xicity and oilier relaied side clVccb, are the most serious problems associated 
witli ilic currently avuilable anticancer ciiugs. Oilier limitations include widespread 
systemic distribution and rapid elimiiiaiioii ofilic atlministered anticancer drugs from 
the host body. A .voridwidc search I'r.ercrorc continues for anticancer drugs that arc 
more potent, less toxic, and manifest minimum imloward effects to the host. Several 
plant derived compounds lia\ c been rcji-oi!. tl tu possess .strong anticancer properties and 
have been shown lo delay, inhibil, or i .-v c:se cancerous growth in an efliective manner. 
For example, perillyl alcoliol (POH), a phint-based compound, has been reported lo 
possess strong anti-cytoto.xic properties :igainst several types of cancer including those 
of breast, pancreatic, and liver,' ' POH is a monoterpene and constituent of essential 
oils from a number of plants: namely. ])eril la (/\'n7/a//7/^',vcc-'/;.v), lavendin,peppermini, 
ginger grass. sa\in, caraway, and celery seeds."" 
Before translating the suitability of a novel compound like POH as a potential 
aniicancer agent in the clinical selling. \<. i.s desirable to address some of the as.soci,ated 
issues like that of its solubility, palatabiiily, and sustained/controlled release in .systemic 
circulalioii. This requires designing of a suitable drug-delivery system that can release 
the drug gradually over a long period f.f ume and, in turn, facilitate its uptake by cancer 
cells and thereby helps in increasing ihc efficacy of the entrapped drug. Polymeric 
rjr.^c 
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